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ABSTRACT
We proposed that known helix-stabilizing, minor-groove 
binding agents such as CC-1065 and its analog, U-71,184, 
might be feasibly targeted to specific mRNA by tethering 
them to antisense oligonucleotides. The CC-1065-tethered 
antisense oligonucleotide might be hyperstabilized to the 
target mRNA and arrest the translation of mRNA.
Our hypothesis is that these agents can bind and 
increase the stability of RNA-DNA duplexes which may occur 
between mRNA and antisense oligonucleotides. To verify our 
hypothesis, we evaluated the ability of CC-1065, U-71,184, 
and distamycin A to bind and hyperstabilize the 20-mer 
sense sequence (51-TTACTTCAGTTATGAGACCA—3') duplexed with 
complementary (antisense) oligonucleotide sequence made 
with phosphodiester (PO), phosphorothioate (PS), or methyl 
phosphonate (MP) linkages.
Sense DNA sequences (20 mer), when duplexed with PO,
PS, or MP DNA oligonucleotides, were saturated at 2, 2, and 
1 CC-1065 molecules per duplex, respectively, or at 1 
molecule of U-71,184 for each duplex. Each molecule of 
CC-1065 and U-71,184 was able to bind to poly(rA)- 
oligo(dT)2u at maximum binding, similarly, a sense RNA 
sequence duplexed with either PO or PS structures was 
saturated at one CC-1065 molecule per duplex.
It was apparent from the melting temperature study 
that CC-1065 was generally more effective than U-71,184
vi
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against DNA-DNA duplexes even if the antisense DNA strand 
has modified backbone structures. Only CC-1065 was able to 
hyperstabilize the RNA-DNA duplex as evidenced by a 29°C 
increase of the melting temperature. U-71,184 and 
distamycin A were able to increase the melting temperature 
of RNA-DNA duplex only about 2°C and 4°C, respectively.
Translation (wheat germ extract) was inhibited in a 
dose-dependent manner at antisense:mRNA ratios ranging from 
10 to 72. Concomitant incubations of the duplexes with 
CC-1065 caused significantly enhanced depression of 
translation at the higher doses. CC-1065 appears to induce 
hyperstabilization between the antisense oligonucleotide 
and the mRNA target and arrest translation. Further 
development of hyperstabilizing antisense oligonucleotide 
structure is amply justified.
vii
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INTRODUCTION
Synthetic, single-stranded, often chemically-modified 
oligodeoxyribonucleotides which can form duplexes with DNA 
or mRNA in a sequence specific manner have been widely used 
as research tools to selectively inhibit the expression of 
numerous cellular genes (Neyses et al., 1991; Wagner et 
al., 1992; Wang et al., 1992). This field is now generally 
referred to as 'antisense oligonucleotide technology'.
This rapidly developing technology may eventually provide 
therapeutic tools against various cancers, and viral, 
parasitic and autoimmune diseases (Ulman and Peyman, 1990).
The majority of the antisense oligonucleotides to date 
have targeted a translation step to inhibit gene 
expression. Theoretically, any step between transcription 
and translation can be arrested by antisense 
oligonucleotides. Antisense oligonucleotides with 
sequence complementary to mRNA can duplex with pre-mRNA or 
mRNA and disrupt mRNA processing and translation (Ulman and 
Peyman 1990). Antisense oligonucleotides can also bind to 
double-stranded DNA with certain sequences and form a local 
triple-helix by Hoogsten base-pairing (Dervan, 1986).
The exact mechanisms by which antisense 
oligonucleotides exert their function are not well- 
understood. Two mechanisms appear to be involved: 1) 
blocking (passive) mechanism (Miller and Ts'o, 1987;
Boiziau et al., 1991) and 2) a RNase H-dependent (reactive)
1
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mechanism (Walder and Walder, 1988; Boiziau et al., 1992). 
According to the first mechanism, antisense 
oligonucleotides can disrupt mRNA processing by masking the 
sites involved in splicing, 5'-capping, 3'-polyadenylation, 
and translation initiation and sterically blocking the 
movement of the ribosomal complex. In the second 
mechanism, mRNA targeted by complementary antisense 
oligonucleotides can be destroyed by the ubiquitous enzyme, 
RNase H. RNase H degrades the RNA strand of RNA-DNA 
duplexes (Wintersberger, 1990). Although, oligonucleotide 
methylphosphonates or a-anomeric oligonucleotides can 
inhibit gene expression without inducing RNase H activity 
(Blake et al., 1985; Agris et al., 1986; Shakin and 
Liebhaber, 1988; Boiziau et al., 1991), RNase H-induced 
degradation of target mRNA appears to be the principal 
mechanism of action for other antisense oligonucleotides 
based on phosphorothioates.
Gene expression is a very complex process that 
requires numerous protein factors and nucleic acid-enzyme 
complexes. Better understanding of the secondary or 
tertiary structure of the mRNA and its biological stability 
should be useful in designing optimum antisense 
oligonucleotides sequences (Freier et al., 1986; Ecker et 
al., 1992; Lima et al., 1992).
To function as efficient therapeutic agents, the 
antisense oligonucleotides should remain at their target
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sites long enough in sufficient concentrations. To attain 
desired half-life and concentrations, the antisense 
oligonucleotides should be resistant to numerous endo- and 
exonucleases and pass through the biological membranes to 
reach the target sites. Satisfactory binding specificity 
and stability of the antisense oligonucleotides can be 
achieved by unmodified oligonucleotides. However 
resistance to nucleases and improved ability to cross cell 
membranes can be achieved by various structural 
modification of oligonucleotides. During the last few 
years, there has been a significant development in the 
field of medicinal chemistry directed toward such 
modifications (Cook, 1991).
Drugs targeted against nucleic acids with high 
specificity can offer several advantages over traditional 
protein-based drug targeting. First, nucleic acids are 
structurally simpler than proteins. Second interaction 
with their targets occurs in an early stage of gene 
expression well before the protein exists. Third, 
statistically, a base sequence for a 17-mer oligonucleotide 
is expected to occur only once in the human genome and 
therefore highly specific target selectivity is assured. 
Thus, oligonucleotides may provide much higher selectivity 
and affinity against their targets than traditional drugs.
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CHAPTER I. LITERATURE REVIEW 
Mechanisms of Action 
Transcription Arrest
In addition to disrupting translation at the mRNA 
level, antisense oligonucleotides can also bind to the 
sense strand of DNA and disrupt transcription initiation 
and elongation by masking the binding sites for protein 
factors needed for transcription initiation and by 
sterically hindering the movement of the transcriptional 
complex. Antisense oligonucleotides can also inhibit 
transcription when conjugated to intercalating, cross 
linking, and sequence-specific cleaving agents. Targeting 
gene expression at the transcriptional level may be more 
efficient than targeting at the translation level, since 
there are fewer copies of genes in the cell than there are 
of mRNA.
Triple-helices can be formed by insertion of 
homopyrimidine strands in the major groove of polypurine- 
polypyrimidine tracts. The sequence recognition and triple 
helix bonding appear to be due to Hoogsten base pairing 
(Dervan, 1986) . Inhibition of transcription elongation 
(Young et al., 1991) and inhibition of transcription of the 
human c-mvc gene (Cooney et al., 1988) using the triplex 
helix concept have been reported. Site-specific cleavage 
of double stranded DNA was achieved with triple-helix 
forming, 20-mer oligonucleotides conjugated with EDTA-Fe
4
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(Strobel et al., 1990). Similarly Dual-Valentin et al. 
(1992) inhibited the transcription initiation of a 267- 
base-pair fragment from plasmid pBR322 using a triple 
helix-forming 13-mer oligonucleotide conjugated with a 
psoralen which was activated by UV light. Inhibition of 
transcription was also reported using 
a-oligodeoxynucleotides conjugated with intercalating 
agents (Sun et al., 1991).
A new type of anti-gene oligonucleotide referred to as 
peptide nucleic acids (PNAs) was recently reported by 
Neilson et al. (1991; 1993). PNAs are capable of invading 
the DNA duplex, causing displacement of one strand and 
forming a very stable displacement loop (D-loop) with the 
complementary DNA strand. Structurally, PNAs are built 
from a polyamide peptide backbone composed of 2- 
aminoethylglycine units (Neilson et al., 1991). PNAs can 
arrest transcription elongation or DNA replication by 
blocking RNA polymerase II and Taq DNA polymerase movement 
(Nielsen et al., 1993). PNAs were also capable of site- 
specific termination of reverse transcription and in vitro 
translation (Hanvey et al., 1992).
Unfortunately targeting DNA using antisense 
oligonucleotides at this time has not been as successful as 
targeting mRNA. These anti-gene oligonucleotide strategies 
have not yet been shown in intact cells.
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Arrest of mRNA Processing
The primary transcript (premature) mRNA in eukaryotic 
cells undergo several maturation processes before they 
finally translocate to the cytoplasm. Messenger RNA 
splicing is a very orchestrated and sequence-specific 
process of excising the non-coding or intermediate (intron) 
segments. This process requires several protein factors 
and small ribonuclear RNAs, the formation of which are now 
being clarified. Antisense oligonucleotides targeted 
against the splicing donor or acceptor sites on either 
exons (coding sequences) or introns (Smith et al., 1986; 
Morrison, 1991; Volloch et al., 1991a; Volloch et al., 
1991b) can arrest splicing by interfering with the binding 
of heterogeneous small nuclear ribonucleoproteins. 
Alternatively RNase H activity could destroy the RNA (vide 
supra).
Eukaryotic primary mRNA is also 5'-capped and 3'- 
polyadenylated. These processes play important roles in 
RNA stability, nuclear transport, or translation 
efficiency. Targeting cap-region sequences of c-mvc mRNA 
results in 2- to 3-fold inhibition of translation over that 
from targeting translation initiation sequence (Bacon and 
Wickstrom, 1991). Boiziau et al. (1991) inhibited the 
translation of rabbit globin mRNA using the capping region 
of the globin mRNA as a target. Chiang et al. (1991) 
inhibited the expression of intercellular adhesion
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molecule-1 by targeting the 3'-untranslated region of that 
mRNA.
Translation Arrest
The majority of antisense oligonucleotides have been 
designed to block translation. The 5'-translation 
initiation regions of mRNA have most commonly been targeted 
by antisense oligonucleotides (Blake et al., 1985; Cazenave 
et al., 1989), however, downstream coding sequences or 3 1- 
untranslated regions can also be targeted (Jayaraman et 
al., 1981; Zerial et al., 1987; Chiang et al., 1991). The 
efficiencies of antisense oligonucleotides against mRNAs 
can be significantly influenced by the structure of the 
oligonucleotide, by the type of cell being treated, and by 
the particular mRNA or region of the mRNA targeted (Chiang 
et al., 1991).
RNA can form self-hybridizing secondary structures 
called 'stem-loop' or other tertiary structures (Ecker et 
al., 1992). These structures may be involved in specific 
functions. First, they can provide additional stability to 
mRNA. Second, they can function as recognition sites for a 
number of proteins and nucleic acids such as trans- 
activation-responsive element (TAR) of HIV-1 (human 
immunodeficiency virus). Thus, by targeting the above 
secondary structural regions, it may be possible to disrupt 
the stability or translation efficiency of mRNA. Vickers 
et al. (1991) made several antisense oligonucleotides which
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were able to target stem-loop structures of the TAR region 
of HIV, resulting in inhibition of the replication of HIV. 
Ribozyme
Ribozymes are short lengths of oligoribonucleotides 
which can catalytically cleave certain RNA sequences 
containing a GUC cleavage sequence (Haseloff and Gerlach,
1988). Ribozymes are normally found in some RNA plant 
viruses where they play an important role in rolling-circle 
type replication (Cech, 1987). The highly conserved 
catalytic center of ribozymes can be flanked by 
oligonucleotides that can hybridize to complementary RNA 
sequences containing cleavage sites. The result of this 
hybridization is a sequence-specific cleavage of target 
RNA.
The major disadvantage of current ribozyme technology 
is the low rate of catalysis which is several orders of 
magnitude smaller than that of protein-catalyzed cleavage. 
Additionally, ribozymes are sensitive to nuclease 
degradation. Ribozyme approaches may be preempted by 
antisense strategies since ribozymes can not be targeted to 
DNA, whereas antisense oligonucleotides can.
The chimeric ribozyme consists of a catalytic center 
flanked by oligonucleotides with phosphorothioate bonds. 
This structure showed increased nuclease resistance and 
enhanced catalytic efficacy (Chowira et al., 1992; Taylor 
et al., 1992; Shimayama et al., 1993). Chen et al. (1992)
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constructed the multi-target ribozyme which can inhibit the 
HIV-1 virus replication by virtue of cleaving up to nine 
highly conserved regions in the env RNA. Dropulic et al. 
(1992) significantly decreased the expression of U5- 
containing RNA in cells chronically infected with HIV-1 by 
introducing the U5 ribozyme into the cells with a 
retroviral vector.
Anti-Protein Agent (APTAMER)
Oligonucleotides can also be used as anti-protein 
agents, which often are referred to as "APTAMER". Based on 
the knowledge of interactions between regulatory protein 
and DNA or RNA, it may be possible to design short 
oligonucleotide sequences that can specifically recognize 
DNA/RNA binding motifs of transcription factors or other 
enzymes and prevent them from binding to the target region. 
Wu et al. (1990) inhibited in vitro transcription by 
masking the polymerase with double-stranded 
oligonucleotides. Wang et al. (1993) developed a 12-mer 
oligonucleotide APTAMER that can bind and inhibit the 
function of thrombin. Further work is needed on APTAMERs 
to evaluate their potential as therapeutic options.
Pharmacokinetics 
Stability to Nucleases
Wickstrom (1986) found that oligonucleotide 
phosphodiesters were degraded within 15 min in fetal calf 
serum and over 2 hr in HeLa cell postmitochondrial
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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cytoplasmic extracts. But they found no detectable 
oligonucleotide degradation over 2 hr at 37°C in a rabbit 
reticulocyte lysate. Akhtar et al. (1991a) found that both 
5 1- and internally 32P-labelled oligonucleotides linked by 
phosphodiester bonds were completely degraded within 30 min 
when they were incubated at 37°C in human serum. They also 
showed that oligonucleotide methylphosphonates and 
oligonucleotide with alternating methylphosphonate and 
phosphodiester internucleotide linkages were more stable 
than both oligonucleotide phosphorothioates and 
oligonucleotide phosphodiesters against phosphodiesterases 
from the cellular extract. Tidd and Warenius (1991) showed 
that 3 1-exonucleases are responsible for most of the 
oligonucleotide degradation. These authors also claimed 
that simple 3 '-terminal modification ("capping") with a 
methylphosphonate diester or a monoester can significantly 
protect the oligonucleotides from degradation without 
compromising their binding affinity. Eder et al. (1991) 
found that single-stranded oligonucleotides were more 
susceptible to nuclease degradation than double-stranded 
oligonucleotides. Those authors also found that degradation 
of the oligonucleotides was sequence-dependent; 
oligonucleotides with pyrimidine at the 3 1 end were more 
rapidly cleaved than oligonucleotides with 3'-purines.
The activity of different nucleases varies 
significantly depending upon their origin. Differences
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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between species and subcellular location (cytoplasmic vs 
nuclear) have been shown (Wickstrom, 1986; Akhtar et al., 
1991a; Eder et al., 1991). As a result, it may be difficult 
to predict the intracellular stability of antisense 
oligonucleotides based only on stability in cell culture 
medium or sera. In general, the activity of nucleases was 
observed in the following order: calf serum > mouse serum > 
human serum > nuclear extract > cytoplasmic extract 
(Wickstrom, 1986; Akhtar et al., 1991a; Eder et al., 1991). 
Cellular Uptake and Intracellular Distribution
Loke et al. (1989) studied the cellular uptake of 
acridine-labelled oligothymidylates with variable lengths 
ranging from 3 to 20 bases. They found that the uptake of 
oligothymidylates in HL60 cells in culture was temperature 
dependent (uptake occurring at 37°C but not at 4°C), size- 
dependent (inversely proportional to their lengths), and 
saturable. The uptake was competitively inhibited by 
oligonucleotides with phosphodiester bonds possessing a 5'- 
phosphate moiety, but not by oligonucleotides with 
methylphosphonate bonds. An 80 kilodalton (kDa) cell 
receptor protein postulated to be involved in the cellular 
uptake of oligonucleotides has been affinity purified from 
cell membrane lysates using oligo(dT) cellulose beads (Loke 
et al., 1989).
Oligonucleotides conjugated to a reactive alkylating 
group labeled two receptor proteins in mouse fibroblast
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
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cells; the proteins were 79 and 90 kDa in size (Yakubov et 
al., 1989). Those authors also found that cellular uptake 
was temperature dependent and was inhibited by endocytosis 
inhibitors such as sodium azide, deoxyglucose, and 
cytochalasin B. They also showed that a significant 
percentage of the total oligomer pool was adsorbed on the 
cell surface and was internalized efficiently by an 
absorptive endocytosis process at concentrations of 
oligonucleotides less than l/uM. In contrast, at moderate 
to high concentration of oligomers, fluid-phase endocytosis 
seems to be the major uptake process.
A 15-mer oligodeoxythymidine containing phosphodiester 
bonds or a 28-mer oligodeoxycytidine with phosphorothioate 
bonds was taken up by HL60 cell by pinocytosis in a time- 
and concentration-dependent manner (Stein et al., 1993b). 
The internalization of fluorescent-labelled albumin, a 
pinocytosis marker, was inhibited by both oligomers. The 
pinocytotic internalization of charged oligonucleotides 
appears to require intact protein kinase C activity, which 
in turn can be inhibited by charged oligonucleotides (Stein 
et al., 1993b).
Kitajima et al. (1992) found that tax-transformed 
mouse fibroblasts, human T-cell leukemia virus type-1- 
transformed human lymphocytes, or phorbol 12-myristate 
activated Balb/3T3 cells showed at least five-fold 
increases in uptaking 19-mer oligodeoxyribonucleotides
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compared to that of control (non-transformed or non­
activated) cells- They also found that uptake of the 
oligonucleotides was increased more than 10 times as the 
concentration of calcium increased or when the medium was 
acidic. Based on the above findings, Kitajima et al.
(1992) proposed that activated cells may express more 
proteins involved in oligonucleotide uptake on their cell 
surface than do non-activated cells. They also suggested 
that protein involved in oligonucleotide uptake may undergo 
post-translational changes sensitive to acid or calcium.
The cellular uptake of 21-mer oligodeoxynucleotide 
phosphodiesters using Rausher Red 5-15 cells showed that 
uptake was partially energy dependent and inhibited by 
charged molecules including oligonucleotides, DNA, and 
dextran (Wu-Pong et al., 1992). The uptake of 21-mer 
oligodeoxyribonucleotides was not significantly inhibited 
by chloroquine or monensin, which are known receptor- 
mediated endocytosis blockers, but was significantly 
inhibited by known anion channel blockers, such as NaCl or 
NH4C1 (Wu-Pong et al., 1992).
Oligonucleotide phosphorothioates appear to be taken 
up by cells through receptor-mediated endocytosis as with 
oligonucleotide phosphodiesters, however the rate of uptake 
was slower than with phosphodiester-based oligonucleotides 
(Stein et al., 1988a). The uptake of phosphorothioate 
homooligomers was also temperature dependent, was inversely
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proportional to the lengths of oligomers and showed 
punctuated intracellular distribution (Stein et al.,
1988a).
Oligonucleotide methylphosphonates were originally 
thought to enter cells by a passive diffusion mechanism 
because they lack charges and are hydrophobic (Miller et 
al., 1981). The efflux (transport) rate of oligonucleotide 
methylphosphonates entrapped within liposomes was similar 
to those of oligonucleotide phosphorothioates, 
phosphodiesters, or oligonucleotide with alternating 
methylphosphonate and phosphodiester bonds (Akhtar et al., 
1991b). The cellular uptake of 15-mer oligonucleotide 
methylphosphonates in Chinese hamster ovary cells showed 
that uptake was highly temperature dependent, with a 
significant increase occurring between 15°C and 20°C (Shoji 
et al., 1991). Rhodamine-labelled oligonucleotide 
methylphosphonates showed co-localization with dextran, 
which is a known endosome and lysosome marker (Shoji et 
al., 1991). The cellular uptake of oligonucleotide 
methylphosphonates was not competitively inhibited by 
excess oligonucleotide phosphodiesters, methylphosphonates, 
nor ATP. Uptake of oligonucleotide methylphosphonates was 
not inhibited by cytoplasmic acidification, but this was 
not the case for phosphodiester-based oligonucleotides 
(Shoji et al., 1991). Based on the above findings, 
oligonucleotide methylphosphonates likely enter cells by an
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active absorptive- or fluid-phase endocytosis rather than 
simple passive diffusion or receptor-mediated endocytosis.
The efficiency of cellular uptake of 
oligonucleotides may be influenced by cell types or growth 
state of the cells. Yakubov et al. (1989) found that the 
efficiency of oligonucleotide internalization decreased as 
the density of cell monolayer increased. Iwanaga and 
Ferriola (1993) reported that cellular internalization of 
oligonucleotide phosphorothioates into rat tracheal 
epithelial cells decreased as the cell density increased. 
Gao et al. (1993) showed that intracellular accumulation of 
oligonucleotide phosphorothioates was greater in carcinoma 
cells than in leukemia cells. Iwanaga and Ferriola (1993) 
suggested that receptor expression or endocytotic activity 
may be different under different growth states. Yakubov et 
al. (1989) and Marti et al. (1992) found that internalized 
oligonucleotides can be exocytosed. Specific fractions 
exocytosed were not stated. The time constant for 
exocytosis of oligonucleotide phosphorothioates was similar 
to that of uptake, however a significant fraction still 
remained in the cell.
Microinjected, fluorescent-labelled oligonucleotides 
rapidly translocated into the nucleus and showed a stippled 
fluorescent pattern throughout the nucleoplasm (Leonetti et 
al., 1991). The nuclear translocation was not affected by 
the intracellular energy pool, by temperature, nor was it
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competitively inhibited by unlabeled oligonucleotides; all 
are compatible with a passive diffusion mechanism. The 
oligonucleotides, once translocated into the nuclei, seem 
to bind to specific 36 to 50 kDa nuclear proteins. Chin et 
al. (1990) found that oligonucleotide phosphodiesters and 
oligonucleotide phosphorothioates are predominantly 
concentrated in the area where small ribonucleoproteins are 
abundant, while oligonucleotide methylphosphonates are 
concentrated near genomic DNA. Clarenc et al. (1993) found 
that oligonucleotides with either phosphodiester or 
phosphorothioester bonds can compete with each other for 
binding sites in the nucleus; however oligonucleotide 
methylphosphonates and a-anomeric oligonucleotides do not 
compete with each other. Those authors also found that a- 
anomeric oligonucleotides bind to nuclear proteins less 
extensively than do oligonucleotides with phosphodiester, 
phosphorothioate, or methylphosphonate bonds.
Oligonucleotides can bind non-specifically and become 
trapped in the proteins or lipid components of cytoplasmic 
organelles or in the nuclear matrix. This can 
significantly influence intracellular distribution of the 
internalized oligonucleotides. Consequently, the degree of 
non-specific binding of internalized oligonucleotides can 
affect their biological activities.
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Delivery Systems for Antisense Oligonucleotides
Synthesis of cholesteryl-conjugated oligonucleotide 
phosphodiesters and phosphorothioates was reported by 
Letsinger et al. (1989). A 10-mer phosphorothioate 
homocytidine conjugated with cholesterol at the 5 '-end 
inhibited syncytium formation and infection of HIV 
presumably by disrupting the DNA polymerase activity of 
reverse transcriptase (Stein et al., 1991). Alkylating 
oligonucleotides containing cholesterol residue at the 3' 
terminal end showed about a 2-fold increase in cellular 
uptake and DNA alkylation compared to oligonucleotides 
lacking 3'-terminal modification (Boutorin et al., 1989). 
Fluorescent-labelled oligonucleotides linked to cholesterol 
at the 5'-end showed increased cellular association and 
internalization of the oligonucleotides by flow cytometry 
(Krieg et al., 1993). Cellular internalization of 
cholesteryl-conjugated oligonucleotides may occur at least 
partially through the low density lipoprotein receptor. 
Extension of the plasma half-life of cholesteryl-conjugated 
antisense oligonucleotide can be accomplished by tethering 
cholesteryl-conjugated oligonucleotides to low-density 
lipoproteins (Smidt et al., 1991).
An approximate 10-fold increase of cellular uptake and 
effective inhibition of vesicular stomatitis virus (VSV) 
protein production was achieved without causing 
cytotoxicity when the oligonucleotides were conjugated to
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1,2-di-0-hexadecyl-3-glyceryl moiety (Shea et al., 1990). 
Inhibition of influenza virus replication and of viral 
protein production was achieved by conjugation of antisense 
oligonucleotides with a hydrophobic, undecyl residue at the 
5 '-end of the oligonucleotide (Kabanov et al., 1990). Will 
and Brown (1991) reported the synthesis of vitamin E-linked 
oligonucleotides. But no biological studies on the vitamin 
E-linked oligonucleotides have been reported.
Oligonucleotides complementary to the translation 
initiation region of VSV N-protein was coupled to e-amino 
groups of lysine residues in poly(L-lysine) (Lemaitre et 
al., 1987). These oligonucleotides inhibited the synthesis 
of VSV proteins when they were added to the cell culture 
medium at a concentration of 100 nM. Inhibition of the 
cytopathic effect of 17-mer oligonucleotides targeted for 
the splicing site of HIV-1 was enhanced when they were 
conjugated with poly-L-lysine (Stevenson and Iversen,
1989). Poly L-lysine-conjugated oligonucleotides appear to 
enter the cell by adsorptive endocytosis resulting from 
interactions with negative charges on the cell membranes 
(Leonetti et al., 1990a). Cell-specific delivery of poly- 
L-lysine conjugated oligonucleotides to pulmonary 
endothelial cells was achieved by attaching a monoclonal 
antibody for cell-surface thrombomodulin (Trubeskoy et al., 
1992) .
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The organ- or tissue-specific delivery and uptake of 
antisense oligonucleotides can be achieved by covalently 
conjugating specific receptor ligands to the 
oligonucleotide/poly-L-lysine complex. Inhibition of 
growth and loss of viability of HL60 leukemia cells were 
achieved by specifically delivering the antisense 
oligonucleotides which are targeted against c-mvb and 
conjugated with transferrin to HL60 leukemia cells. These 
cells have unusually high numbers of transferrin receptors 
on their cell surfaces (Citro et al., 1992). Wu and Wu 
(1992) specifically inhibited the hepatitis B viral gene 
expression in the hepatocytes transfected with hepatitis B 
virus by treating the cells with antisense oligonucleotides 
conjugated with hepatocyte-specific glycoprotein.
Antisense oligonucleotides conjugated with a 
neoglycoprotein such as, 6-phosphomannosylated albumin, 
showed about 20-fold increases in cellular uptake compared 
to normal unconjugated oligonucleotides (Bonfils et al., 
1992b). The internalized oligonucleotides showed vesicular 
distribution patterns throughout the cytoplasm. Cell- 
specific delivery of antisense oligonucleotides to 
macrophages was achieved by linking a macrophage-specific 
mannosylated-streptavidin complex to biotinylated antisense 
oligonucleotides (Bonfils et al., 1992a). Avidin, a 
cationic protein, was able to enhance the uptake of 
biotinylated oligonucleotides, probably through increased
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binding affinity of avidin to negatively charged molecules 
on the cell surface (Pardridge and Boado, 1991) . These 
molecular conjugation strategies might be a very useful 
methods to deliver antisense oligonucleotides to desirable 
target organs or cells.
Liposomes are stable microscopic vesicles made of 
phospholipids and other amphipathic lipids (Fielding,
1991). Liposomes present a potentially useful strategy to 
enhance the cellular delivery and uptake of the antisense 
oligonucleotides (Loke et al., 1988; Oberhauser and Wagner,
1992). It may possible to target liposomes to specific 
cells by attaching antibodies to the liposomal surface. 
Sequence-specific and dose-dependent suppression of VSV 
titers in L929 cells was achieved by specifically 
delivering the antisense oligonucleotides using liposomes 
that have attached H2K antibodies (Leonetti et al., 1990b). 
Liposomes containing antisense oligoribonucleotides 
directed against the env region of HIV can be specifically 
targeted to HIV-infected T lymphocytes using anti-CD3+ 
antibodies (Renneisen et al., 1990). This approach has 
shown strong inhibition of the expression of HIV-l.
Although liposomes can increase the stability, targeted 
cellular delivery and uptake of antisense oligonucleotides, 
there are two major limitations in current liposome 
technology. The two major limitations are that they are
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poorly encapsulated into the liposome vesicles and that 
most of them are degraded in the lysosomes.
Akhtar et al. (1991b) reported an increased 
encapsulation efficiency of large multilamellar vesicles 
using a freeze and thaw technique. The encapsulation ratio 
of oligonucleotide methylphosphonates and phosphorothioates 
was approximately 10-times better than the standard 
multilamellar preparation method. The freeze and thaw 
process did not cause oligonucleotide degradation. 
Oberhauser and Wagner (1992) synthesized 2'-O-methyl 
oligoribonucleotides that were coupled to thiocholesterol 
through a disulfide bridge. These oligonucleotides showed 
about 6-fold increased encapsulation efficiency when 
prepared by a reverse-phase evaporation method compared to 
those with unmodified 2'-O-methyl ribonucleotides. As 
shown by Feener et al. (1990), cleavage of oligonucleotides 
from disulfide bonds was observed once oligonucleotides 
were internalized.
Liposomes are known to enter the cells through 
endocytosis (Heath, 1987). Therefore the efficiency of 
antisense oligonucleotide delivery using liposomes still 
may be limited since the majority of the oligonucleotides 
will probably be degraded in lysosomes. Degradation of 
oligonucleotides in the endosome/lysosomal compartment may 
be reduced by bypassing endocytosis or by using pH- 
sensitive liposomes.
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Bennett et al. (1992) used cationic lipid vesicles, 
often referred to as 'lipofectin', to enhance the cellular 
uptake of oligonucleotide phosphorothioates. Lipofectin 
has been used to enhance gene transfection (Behr et al., 
1989; Feigner and Ringold, 1989). Structurally, 
lipofectins are composed of N[l-(2,3-dioleyloxy)propyl]- 
N,N,N-trimethylammonium and phosphatidyl ethanolamine. The 
uptake of oligonucleotides using lipofectins was 
significantly improved, resulting in increased cytoplasmic 
and nuclear accumulation. Lipofectins are known to enter 
the cells by membrane fusion rather than by endocytosis as 
other conventional liposomes do (Feigner et al., 1987).
Two major shortcomings of lipofectins are that they are 
toxic to certain cells and they can fuse nonspecifically 
with cells.
Collins and Huang (1987) developed a pH-sensitive 
immunoliposome which can significantly enhance the 
cytotoxic potential of a Diphtheria toxin A fragment in 
toxin-resistant murine cells without causing nonspecific 
cytotoxicity. The antisense oligonucleotides targeted 
against Friend leukemia virus encapsulated in pH-sensitive 
liposomes inhibited the viral foci formation more strongly 
than those encapsulated in normal liposomes (Ropert et al.,
1992). Endocytosis uptake of liposomes can also be 
bypassed by using liposomes that have attached viral
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proteins which induce membrane fusion (Lapidot et al.,
1990; Gould-Fogerite, 1989).
Chavany et al. (1992) developed a nanoparticle method 
as a possible carrier system for antisense 
oligonucleotides. Oligothymidylates were adsorbed to 
polyisobutyl- or polyisohexylcyanoacrylate nanoparticles in 
the presence of hydrophobic cations. The adsorption was 
due to ion-pair formation between the negatively charged 
phosphate groups of the nucleic acids and the hydrophobic 
cations. They found that the adsorption efficiency of 
oligonucleotides was highly influenced by the length of 
oligonucleotides, by the hydrophobicity of cations used as 
ion-pairing agents, and by the composition of the 
cyanoacrylic monomer. Additionally, the adsorbed 
oligonucleotides were stable against 3'-exonucleases.
In Vivo Pharmacokinetics
Little information regarding the in vivo 
pharmacokinetics of antisense oligonucleotides has been 
reported. Agrawal et al. (1991) showed that 20-mer 
oligonucleotide phosphorothioates at concentration of a 30 
mg/kg body weight by iv or ip injection were rapidly 
cleared from the blood and distributed to most tissues 
except brain as intact 20-mers. About 30% of the injected 
oligonucleotide phosphorothioates were excreted in urine 
within 24 hr (Agrawal et al., 1991). A single 
administration of a 27-mer anti-HIV rev oligonucleotide
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phosphorothioate to the rat by iv or ip injection revealed 
a half life of 20-40 hr for elimination from the body 
(Iversen, 1991). This suggests that repetitive doses can 
maintain a therapeutic concentration in the body. Indeed, 
after repeated daily injections, a steady state was reached 
in about 6 to 9 days. A 12-mer oligonucleotide 
methylphosphonate administered to mice by injection through 
the tail vein was rapidly cleared and distributed 
throughout all organs, including brain. Half-life of 6 and 
17 min for distribution and elimination, respectively, was 
observed (Chen et al., 1990). About 70% of the total dose 
of 12-mer oligonucleotide methylphosphonate was excreted in 
the urine over 60 min (Chin et al., 1990). Approximately 
20 to 30% of a 38-mer, 3' phosphopropyl amine 
oligonucleotide was excreted in the urine over 8 hr. 
Micromolar concentrations of intact oligonucleotides were 
detected in various tissues at 8 hr after injection 
(Zendegui et al., 1992).
Pharmacodynamics 
Two primary factors which can influence the 
hybridization efficiency of antisense oligonucleotides with 
their targets are stability of the duplex and specificity 
of the antisense oligonucleotides-target interaction.
Since Watson-Crick base pairing is the primary driving 
force for duplex formation, the stability of the duplex 
will increase as a function of duplex length. The degree
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of stability is evaluated by measuring the melting 
temperature (Tm) at which half of the duplex is dissociated 
into single strands. Under normal physiological 
conditions, antisense oligonucleotides should be at least 
15 to 18 bases long to maintain sufficient hybridization to 
yield significant biological effects. The stability of 
DNA-DNA (Breslauer et al., 1986) or RNA-RNA (Freier et al., 
1986) duplexes can be predicted by the nearest-neighbor 
rule.
Given the size of the genome and the number of genes 
in cells, one can predict on a statistical basis that the 
shortest unique mRNA sequence in a cell will be 13 bases 
long (Helene and Toulme, 1989). Therefore, 
oligonucleotides ranging from 11 to 15 in length should 
provide enough specificity to ensure unique targeting of a 
gene. However, this may still allow some nonspecific 
interactions, since Woolf et al. (1992) found cleavage of 
non-target mRNA by partially hybridized antisense 




One or both oxygens not engaged in the 
phosphodiester linkages can be replaced by other atoms or 
functional groups. Examples of such modified structures 
include phosphorothioates (Stec et al., 1984; Stec and Zon,
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1985; Zon and Geiser, 1991), phosphorodithioates (Marshall 
et al., 1992; Marshall and Caruthers, 1993), 
methylphosphonates (Miller et al., 1981; Mill et al.,
1986), phosphoramidates (Agrawal et al., 1988), 
phosphotriesters (Marcus-Sekura, 1987), and 
oligonucleotides with boronated phosphates (Sood et al., 
1990).
The synthesis of oligonucleotide phosphorothioates was 
originally reported by Stec et al. (1984) and Stec and Zon 
(1985). In oligonucleotide phosphorothioates, one of the 
oxygens not involved in phosphodiester linkages is replaced 
by a sulfur atom.
Oligonucleotide phosphorothioates are soluble in water 
and are more stable against exo- and endonucleases than are 
normal oligomers (Stein et al., 1988b). They are digested 
by SI endonuclease and by nuclease PI about 2 to 45 times 
slower than normal oligomers and are slowly digested by 
snake venom phosphodiesterase (Stein et al., 1988b). The 
enhanced nuclease resistance of oligonucleotide 
phosphorothioates occurs because certain nucleases can 
cleave oligonucleotides in either R or S configurations: 
snake venom phosphodiesterase is only active against 
oligonucleotides in the R configuration (Burgers et al., 
1979) ; however, SI and PI nucleases are only active against 
oligonucleotides in the S configuration (Potter et al.,
1983) .
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Oligonucleotide phosphorothioates were also capable of 
inducing RNase H activity as were phosphodiester-based 
oligonucleotides (Agrawal et al., 1990). RNase H activity 
against poly rA duplexed with 40-mer phosphorothioate-based 
oligothymidylates was significantly greater than that 
duplexed with 40-mer phosphodiester thymidylates (Stein et 
al., 1988b). For 40-mer dA-dT oligomers, the melting 
temperature of the duplex containing phosphorothioates was 
about 15°C to 20°C lower than that of phosphodiester-based 
oligomers. But the differences become less significant as 
the lengths of the oligonucleotides increased (Stein et 
al., 1988b). Oligonucleotide phosphorothioates are known 
to hybridize with their complementary strands about 4 to 8 
times slower than do phosphodiester-based oligomers of the 
same length (Young and Wagner, 1991).
One drawback of oligonucleotide phosphorothioates is 
their non sequence-dependent cytotoxicity. Oligonucleotide 
phosphorothioates have been shown to bind nonspecifically 
to DNA-polymerase, topoisomerase, and RNase H (Gao et al., 
1992). Total numbers of these internucleotide linkages in 
the oligomer, rather than their positions, is most relevant 
to toxicity (Gao et al., 1992). A 28-mer 
oligodeoxycytidine with phosphorothioate bonds (S-dC28) 
inhibited the viral replication and cytopathic effects of 
HIV (Matsukura et al., 1987). Majumdar et al. (1989) 
suggested that non-sequence-specific effect of S-dC28 was
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probably due to competitive inhibition of S-dC28 with 
primer-template binding of reverse transcriptase. S-dC28 
also inhibited herpes simplex virus-2 polymerase and human 
DNA polymerase (Gao et al., 1989). Stein et al. (1993a) 
proposed that, by binding to the third variable loop domain 
of the gpl20 protein of HIV, oligonucleotide 
phosphorothioates may exert their cytoprotective effect in 
part by competitively inhibiting the binding of HIV-l 
envelope protein to CD4+ lymphocytes. Oligonucleotide 
phosphorothioates were effective against cells chronically 
and acutely infected with HIV (Matsukura et al., 1989).
Oligonucleotide methylphosphonates are 
oligonucleotides in which one of the oxygens on the 
phosphodiester linkage is replaced by a methyl group 
(Miller et al., 1981; Jayaraman et al., 1981; Miller et 
al., 1986). Oligonucleotide methylphosphonates are 
nuclease-resistant (Agrawal and Goodchild, 1987). 
Oligonucleotide methylphosphonates have three limitations. 
First, they have a lower hybridization efficiency and 
duplex stability than do oligonucleotides with 
phosphodiester bonds (Maher and Dolnick, 1988; Lesnikowski 
et al., 1990). Second, oligonucleotide methylphosphonates 
do not induce RNase H activity (Furdon et al., 1989;
Quartin et al., 1989). Third, they have low water 
solubility.
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Substitution of an oxygen in the internucleotide bonds 
with a methyl group causes the internucleotide linkage, as 
with phosphorothioates, to become chiral. The R and S 
forms caused reduced helix stability (Lesnikowski et al., 
1990), presumably by altering conformation of the 
oligomers. Despite lacking the ability to induce RNase H 
activity, oligonucleotide methylphosphonates were able to 
inhibit viral replication and the cytopathic effects of HIV 
(Sarin et al., 1988) and herpes simplex virus (Smith et 
al., 1986). They were also used to inhibit the activity of 
the multi-drug resistance gene (Vasanthakumar et al.,
1989). Giles and Tidd (1992) developed chimeric 
oligonucleotides with alternating methylphosphonate and 
phosphodiester bonds which can trigger RNase H. These 
combinations will overcome the poor water solubility of 
oligonucleotide methylphosphonates.
Nielsen et al. (1988) synthesized oligonucleotide 
phosphorodithioates in which both oxygens not involved in 
phosphodiester linkages were replaced by sulfur atoms.
These internucleotide bonds are not chiral. Sequence- 
independent inhibition of syncytia formation and inhibition 
of de novo infection of target cells by HIV infection was 
achieved using a phosphorodithioate oligodeoxycytidine and 
without nonspecific cytotoxicity (Marshall et al., 1992). 
The inhibitory effect became stronger as the lengths and 
numbers of the phosphorodithioate bonds increased. The
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inhibitory effect of 14-mer oligonucleotide 
phosphorodithioates was as effective as that of 28-mer 
oligonucleotide phosphorothioates (Marshall et al., 1992). 
Oligonucleotide phosphorodithioates appeared to inhibit the 
function of the enzyme by binding to the enzyme site 
required for the template and primer interaction (Marshall 
and Caruthers, 1993).
The phosphodiester linkers can be replaced partially 
or entirely by various functionalities while maintaining 
the geometry and spacing required for good hybridization. 
Examples of phosphate replacement include; methylene group 
replacing of the phosphorus dioxygen moiety (Matteucci, 
1990), methyl sulfonyl moiety replacing phosphorus and 5'- 
oxygen moiety (Musicki and Widlanski, 1991), dimethyl 
sulfonate replacing 3'-0-P02-0 (Schneider and Benner,
1990) , and acetamido groups replacing phosphorus and its 
3'-oxygen (Nyilas et al., 1990). The oligonucleotides with 
these modified internucleotide structures will be achiral 
and neutral. Therefore oligonucleotides with modified 
linkages will have high nuclease resistance and are 
expected to show significant enhancement in hybridization 
stability. However, the lack of water solubility due to 
neutral charge and difficult chemical syntheses may limit 
the potential of this types of oligonucleotides. Little 
regarding pharmacokinetic or pharmachodynamic behavior of 
these backbone-modified oligonucleotides in biological
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systems appear to have been done. Since nothing has been 
reported, the usefulness of these structures is still too 
early to predict.
Modification of Sugar
a-Anomeric oligonucleotides are oligonucleotides in 
which the glycosyl bond is in the a rather than 
conventional J3 configuration (Morvan et al., 1987a; Morvan 
et al., 1987b). These oligonucleotides form parallel 
rather than antiparallel duplexes with complementary 
strands and adopt a right-handed, B-type helix when they 
form duplexes with single-stranded DNA (Morvan et al., 
1987b). They are soluble in water, are highly nuclease- 
resistant (Bacon et al., 1988), but lack RNase H inducing 
activity (Morvan et al., 1987a). Oligonucleotides with 
a-anomeric configurations have lower stability when 
duplexed with complementary B-anomeric oligonucleotides 
than do normal 6-anomeric configuration (Paoletti et al., 
1989; Morvan et al., 1991).
a-Oligothymidylates covalently linked with a 3- 
azidoproflavine derivative formed a triplex-helix with 
(dA)8.(dT)8 in a parallel orientation to (dA)8 and showed 
cleavage of the DNA after treatment with piperidine (Le 
Doan et al., 1987). Antisense a-oligonucleotides targeted 
against capping or translation initiation regions of the 
rabbit globin mRNA were studied (Boiziau et al., 1991). 
These agents inhibited the translation of rabbit globin
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mRNA in both rabbit reticulocyte lysate and wheat germ 
extract systems in a dose-dependent manner (Boiziau et al.,
1991). By forming a parallel duplex with mRNA template, 
a-oligomeric primers were able to block the reverse 
transcription activity of Moloney murine leukemia virus 
(Lavignon et al., 1989). Morvan et al. (1991) developed a 
12-mer, a-phosphorothioate analog which was targeted 
against the splice acceptor site of the HIV transactivator 
gene. The analog strongly inhibited the replication of HIV 
in cultured MT-4 cells. a-Anomeric, oligodeoxycytidine 
with phosphorothioate and phosphorodithioate bonds was 
capable of inhibiting HIV reverse transcriptase (Morvan et 
al., 1991).
Several oligonucleotides with modified 2'-sugar 
functions have been studied as options to provide enhanced 
affinity for and increased hybridization stability with 
target mRNA (Inoue et al., 1987a; Sproat et al., 1989; 
Kawasaki et al., 1993; Lamond and Sproat, 1993; Monia et 
al., 1993). Those modified structures have C3-endo 
conformation and thus can form A-type helices with mRNA 
targets. Examples of 2'-modified oligoribonucleotide 
structures include 2'-0-methyl (Inoue et al., 1987a; Inoue 
et al., 1987b; Sproat et al., 1989) and 2'-alkyl (Iribarren 
et al., 1990; Lamond and Sproat, 1993). Physicochemical 
studies of oligonucleotides that have modified 2'-0-methyl 
(Inoue et al., 1987a; Sproat et al., 1989) or 2'-0-alkyl
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functions (Iribarren et al., 1990; Lamond and Sproat, 1993) 
revealed greater duplex stability than did
oligoribonucleotides not modified at the 2' position. They 
also showed strong nuclease resistance. However, they lack 
RNase H-inducing ability (Shibahara et al., 1989). Inoue 
et al. (1987b) and Shibahara et al. (1989) reported that 
oligonucleotide phosphorothioates modified with 2'-O-methyl 
groups were nuclease resistant and induced RNase H. 
Shibahara et al. (1989) found that only 2 '-O-methyl 
modified oligonucleotides with phosphorothioate bonds were 
active against HIV in MT-4 cells; however 2'-O-methyl 
oligonucleotides with phosphodiester bond were not 
effective.
A series of oligodeoxyribonucleotides with 2'-fluoro 
(Kawasaki et al., 1993) or 2 '-alkyl (Monia et al., 1993) 
modified structures were synthesized recently. By 
uniformly modifying the 2' position of deoxyribose, 
oligodeoxyribonucleotides can mimic RNA C3-endo sugar 
puckering and form an A-like duplex with target mRNA. This 
results in enhanced helix stability with RNA. The 
stability occurred in the order: 2'-0-fluoro> 2 '-O-methyl > 
2 '-O-propyl > 2 '-0-pentyl > 2'-deoxy (Monia et al., 1993). 
However, oligodeoxyribonucleotides modified at the 2' 
position with phosphodiester bonds are susceptible to 
nucleases and cannot activate RNase H (Kawasaki et al.,
1993). Monia et al. (1993) developed 2 '-modified
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oligonucleotides with phosphorothioate bonds which are 
nuclease-resistant and are capable of inducing RNase H 
activity.
Seliger et al. (1991) developed oligonucleotides with 
terminal 5'-5' and/or 3'-3' internucleotide linkage; these 
were denoted as "terminally inverted polarity". These 
modifications resulted in enhanced resistance to snake 
venom phosphodiesterase and to nucleases in human serum but 
did not absolutely disrupt duplex stability. These 
oligonucleotides were able to inhibit the translation of T- 
antigen in COS-1 cell culture system. Koga et al. (1991) 
synthesized 28-mer a ,B-oligothymidylates with alternating 
3'-3' and 5'-5' internucleotide phosphodiester linkages. 
They were strongly nuclease resistant and showed stability 
similar to those exhibited by 28-mer oligonucleotide 
phosphorothioates when they were duplexed with 28-mer 
oligoadenylates.
Carbocyclic modified oligonucleotides (carbo- 
oligonucleotides), in which the oxygen atom in the 
deoxyribose ring is replaced by a methylene group was 
developed by Perbost et al. (1989) and Sagi et al. (1990). 
Carbo-oligodeoxythymidylates were about 5 times more stable 
against nucleases than were normal oligonucleotides. These 
agents were able to form more stable duplexes with 
oligoadenylates than were unmodified oligodeoxythymidylates 
(Perbost et al., 1989). Carbocyclic-thymidylates inhibited
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DNA polymeration and reverse transcription (Sagi et al., 
1990). Morvan et al. (1990) synthesized a-and D-L- 
octathymidylates which were very stable against 
endonuclease SI and calf spleen phosphodiesterase; however 
these agents failed to form a stable duplex with J3-D-dA8 
and poly rA and therefore, may not be a useful analog. 
Modification of Bases
Only a few examples of chemical modifications have 
been applied to the base moiety of oligonucleotides.
Sanghvi et al. (1991) synthesized a series of antisense 
oligonucleotides containing pyrimidines modified at either 
the 5 or 6 position with various groups. Among the 
modified structures, oligonucleotides containing 6- 
azathymidine residues were strongly resistant to nucleases, 
but maintained hybridization properties similar to that of 
unmodified oligonucleotides. Duplexes with these agents 
are capable of inducing RNase H activity. Deoxyuridine 
conjugated with an electrophilic alkylating 3- 
(iodoacetamido)propyl at the 5 position was synthesized by 
Meyer et al. (1989). Tetradeca oligodeoxynucleotides 
containing alkylating electrophiles hybridized and cross- 
linked to the 7 position of a guanine of the complementary 
strand. This caused strand cleavage following depurination 
of the cross-linked guanine (Meyer et al., 1989). Wagner 
et al. (1993) synthesized oligodeoxynucleotide
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phosphorothioates containing the C-5 propyne analogs of 
uridine and cytidine which can bind RNA with high affinity. 
Conjugated Oligonucleotides
Numerous functional groups have been tethered to 
oligonucleotides to improve their pharmacodynamic and 
pharmacokinetic properties. The functional groups can be 
tethered to either the 5'- or the 3-1 end of 
oligonucleotides through phosphorylating reagents or 
modified linkers.
Asseline et al. (1984a) increased the stability of 
oligonucleotide duplexes by conjugating intercalating 
agents to oligonucleotides. Duplexes with attached 
intercalating agents displayed enhanced stability with 
increases in melting temperature of as much as 15°C 
(Asseline et al., 1984a). The stabilization of duplexes by 
intercalating agents was dependent upon the length of the 
polymethylene linker (Asseline et al., 1984a) and the 
attachment site of this linker on the oligonucleotide 
(Asseline et al., 1984b). Zerial et al. (1987) showed the 
potential utility of the tethered intercalating agent- 
oligonucleotide complex by the selective inhibition of the 
cytopathic effect of type A influenza virus in MDCK cell 
cultures.
Cross-linking of antisense oligonucleotides to their 
complementary stands can be achieved with liganded 
photoactivable cross-linkers. Lee et al. (1988)
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synthesized psoralen-derivatized methylphosphonate 
oligonucleotide targeted against rabbit globin mRNA. These 
agents cross-linked the rabbit globin mRNA and strongly 
inhibited its translation in a rabbit reticulocyte lysate 
system (Kean et al., 1988).
Sequence-specific cleavage of nucleic acids was 
accomplished by conjugating alkylating or oxidative agents 
to the oligonucleotides. For example, Dreyer and Dervan 
(1985) synthesized EDTA-conjugated oligonucleotides. These 
agents caused site specific cleavage over a range of 16 
nucleotides at the site of hybridization in the presence of 
Fe(II), 02, and dithiothreitol. Phenazine Di-N-oxide- 
conjugated antisense oligonucleotides were able to cleave 
the complementary strand by a reductive mechanism (Nagai 
and Hecht, 1991). Recently Zarytova et al. (1993) 
developed bleomycin As-conjugated oligonucleotides.
In Vivo and In Vitro Toxicology
The toxicity of antisense oligonucleotides seems to be 
highly dependent upon the length, concentration, duration 
of the treatment, or the cell types used in the studies. 
Oligonucleotides generally showed some cytotoxicity whether 
phosphodiester bonds were modified or not; however, the 
concentration of oligonucleotide necessary for sequence- 
dependent effect of antisense oligonucleotides is generally 
5- to 10-fold lower than the concentration required for 
cytotoxicity (Smith et al., 1986; Matsukura et al., 1987;
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Cazenave et al., 1989). The degree of nonspecific 
cytotoxicity increases with the length of antisense 
oligonucleotides (Matsukura et al., 1987; Cazenave et al.,
1989). It was found that a 50 n M  concentration of a 28-mer 
oligodeoxycytidine was not toxic to HeLa cells (Gao et al.,
1990); however, Xenopus oocytes showed toxicity when they 
were exposed to less than 0.5 mM of the 28-mer 
oligodeoxycitidine (Cazenave et al., 1989).
At present, not enough in vivo biological studies have 
been performed to draw a general conclusion regarding in 
vivo toxicity of antisense oligonucleotides. Several 
successful applications of antisense oligonucleotides in 
animals have been reported without any significant toxicity 
(see In Vivo Experiment section). Branda et al. (1993) 
reported that antisense oligomers complementary to the rev 
gene of HIV-1 were mitogenic and stimulated immunoglobulin 
production in normal mouse spleen mononuclear cells and 
human peripheral blood mononuclear cells. They caused 
massive splenomegaly and polyclonal hypergammaglobulinemia 
(Branda et al., 1993). The possibility of immunogenicity 
of the oligonucleotides following long-term administration 
deserves strong consideration as a possible non-specific 
side effect.
Applications
Antisense oligonucleotide technology is projected to 
be a future powerful selective therapeutic tool against a
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variety of cancers, viral, retroviral, parasitic, and 
autoimmune diseases. Several in vitro systems, such as 
rabbit reticulocyte or wheat germ translation systems, as 
well as cell cultures and Xenopus oocyte systems have been 
used to evaluate the biological activity of antisense 
oligonucleotides. Since the in vitro study results of the 
antisense oligonucleotides are highly variable and depend 
upon the system used, it will be difficult to predict the 
in vivo activity of antisense oligonucleotides simply based 
on the in vitro data. This along with absorption, organ or 
tissue distribution, metabolism, and excretion are factors 
that will affect in vivo activity of antisense 
oligonucleotides. Antisense oligonucleotides targeted for 
iun (Smith and Prochownik, 1992), c-rovb (Raschella et al., 
1992; Ratajczak et al., 1992a), c-mvc (Collins et al.,
1992; Biro et al., 1993), c-src (Amini et al., 1986), c-kit 
(Catlett et al., 1991), BCL2 (Reed et al., 1990), or ras 
(Yu et al., 1989; Daaka and Wickstrom, 1990; Chang et al.,
1991) oncogenes clearly revealed that they are capable of 
inhibiting the proliferative activity and cause reversion 
of neoplastic cells to their normal phenotypes. Inhibition 
of smooth muscle cell proliferation and tumor cell 
proliferation was accomplished by blocking the genes coding 
for the proteins involved in the DNA replication, such as 
proliferating cell nuclear antigen (Speir and Epstein,
1992) and pl20 (Perlaky et al., 1993). Hara et al. (1991)
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showed that extension of the life span of human diploid 
fibroblast cell line, TIG-1, was achieved by treating the 
cells with antisense oligonucleotides targeted against both 
p53 and pl05 tumor suppressor genes. Thus the immortality 
in tumor cells may, in part, be due to loss of full 
expression of these genes. Rat-1 fibroblast cells treated 
with antisense oligonucleotides targeted against the DCC 
(deleted in colorectal cancer) gene (which is a colorectal 
tumor-suppressor gene involved in cell adhesion) developed 
a rapid and anchorage-independent growth with tumorigenic 
potential in nude mice (Narayanan et al., 1992). The human 
multi-drug resistant tumor cell line, SKVLB, showed 
decreased P-glycoprotein production and increased 
doxorubicin sensitivity after treatment of the cells with 
liposome-encapsulated, 15-mer phosphorothioate 
oligonucleotides directed against the multi-drug resistance 
gene (Thierry et al., 1993). Successful inhibition of 
malignant transformation and tumor growth has been achieved 
by specifically inhibiting the expression of genes encoding 
epidermal growth factor-receptor (Moroni et al., 1992), 
basic fibroblast growth factor (Murphy et al., 1992), or 
thrombospondin (Castle et al., 1991).
Since the pioneering work of Zamecnik and Stephenson 
(1978) on effects of antisense oligonucleotide on Rous 
sarcoma virus, antisense oligonucleotides with various 
internucleotide structures have been used to disrupt viral
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replication and cytopathic effects by targeting various 
viral genes. These genes include those derived from HIV 
(Matsukura et al., 1987; Goodchild et al., 1988), herpes 
simplex virus (Smith et al., 1986; Kmetz et al., 1991), VSV 
(Agris et al., 1986), hepatitis B virus (Goodarzi et al.,
1990), and bovine papilloma virus (Cowsert et al., 1993).
Synthetic oligonucleotides designed against the 
dihydrofolate reductase-thymidylate synthetase gene system 
inhibited the growth of both chloroquine-resistant and - 
sensitive strains of Plasmodium falciparum in in vitro 
culture systems (Rapaport et al., 1992). Cultured 
Trypanosome brucei were killed by acridine-linked antisense 
oligonucleotides directed against the common 5' end of 
Trypanosome brucei (Verspieren et al., 1987).
In Vivo Experiments
Successful extension of survival time accompanied by 
decreased tumor cell infiltration was achieved by treating 
tumor-bearing, SCID (severe combined immunodeficient) mice 
for 7 to 14 days with antisense oligonucleotides targeted 
for c-mvb using miniosmotic pumps (Ratajczak et al.,
1992b). Subcutaneously transplanted NIH 3T3 cells 
transformed by K-ras showed decreased expression of ras 
protein and decreased tumor growth after treatment of 
animals with antisense oligonucleotides targeted for the K- 
ras oncogene (Gray et al., 1993). Intravenously 
administered oligonucleotide methylphosphonates directed
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against c-mvc downregulated the production of c-mvc protein 
in lymphocytes from transgenic mice containing a murine 
immunoqlobulin/c-mvc fusion gene without any evident 
cytotoxicity (Wickstrom et al., 1992). Phosphodiester- 
based, N-mvc antisense oligonucleotides perfused 
subcutaneously with a microosmotic pump were found 
effective against neuroectodermal tumor subcutaneous 
xenografts and specifically downregulated the expression of 
N-mvc proteins (Whitesell et al., 1991). The growth of 
human lung cancer cells orthotopically implanted in the 
lung of nude mice was significantly decreased by 
intratracheally administered, antisense K-ras retroviral 
constructs (Georges et al., 1993).
Using a rat carotid artery injury model, Simons et al. 
(1992) showed a marked inhibition of smooth muscle cell 
proliferation and migration by locally delivered c-mvb 
antisense oligonucleotides. Subcutaneous injection of 
antisense oligonucleotides targeted against the gene 
encoding IL-1 receptor significantly inhibited the 
infiltration of neutrophils following IL-1 injection (Burch 
and Mahan, 1991). Oligonucleotide phosphorothioates 
directed against the 51 region of the pre-S gene of duck 
hepatitis B virus (DHBV) were injected iv into Pekin ducks 
which were previously infected with DHBV. This treatment 
specifically inhibited viral replication (Offensperger et 
al., 1993).
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CC-1065 (Fig. 1) is a potent antitumor antibiotic 
agent which was isolated from the fermentation liquor of 
Streptomvces zelensis (Hanka et al., 1978; Martin et al.,
1981). Because it caused lethal toxicity, its development 
as a new anticancer agent was suddenly halted (McGovren et 
al., 1984). The toxicity was unusual in that deaths were 
delayed until 30 to 70 days after administration of a 
subtherapeutic dose in non-tumor bearing mice. The lethal 
delayed effects were associated with hepatic toxicity and 
mild renal and bone marrow toxicity after a single iv dose 
of CC-1065 at 12.5 Mg/kg body weight, or after a single ip 
dose at 10 jxg/kg body weight. Mice treated with high doses 
of CC-1065 (400-800 Mg/kg body weight) died within 2 weeks 
due to hepatic necrosis. Ultrastructural changes of the 
mitochondria after five daily doses at 12.5 /xg/kg/day were 
characterized by swelling and hypersegmentation of the 
cristae of mitochondria and calcium accumulation. Delayed 
toxicity appears to be due to the disruption of the 
mitochondrial morphology and function following the binding 
of CC-1065 to the mitochondrial DNA (Swenson, D. H., 
Louisiana State University, personal communication).
Delayed deaths with low dose of CC-1065 were also seen in 
the rabbit (McGovren et al., 1984).
CC-1065 was originally found to bind only to double­
stranded DNA but not to denatured DNA or yeast RNA (Li et



















Fig. l. chemical Structure of CC-1065, 
U-71,184, and Distamycin
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al., 1982). This binding was rapid and dose-dependent 
(Bhuyan et al., 1982; Li et al., 1982). Only 0.02 ng/xnl of 
CC-1065 was required to inhibit cell growth by 50%. The 
potency of this drug was obvious by comparison to 
adriamycin and actinomycin D which were about 400 and 80 
times less potent than CC-1065, respectively (Li et al., 
1982) . Inhibition of DNA synthesis may be the major mode 
of action of CC-1065 (Li et al., 1982; Swenson et al.,
1982), since synthesis of this macromolecule was suppressed 
at lower dose than those required to inhibit synthesis of 
RNA or protein. CC-1065 binds covalently to AT-rich sites 
in the minor groove of DNA as shown by several facts 
(Swenson et al., 1982). First, CC-1065 inhibited chemical 
methylation or ethylation of DNA only at minor groove, but 
not major groove sites. Second, CC-1065 bound to T-4 phage 
DNA, which is glycosylated at the major groove, to nearly 
the same extent as it did to calf thymus DNA. Third, 
binding was competitively inhibited by netropsin (binds to 
AT-rich sites in the minor groove of DNA) but only 
partially by anthramycin (binds to GC-rich sites in the 
minor groove).
CC-1065 hyperstabilizes the duplex once it covalently 
binds to the duplex (Swenson et al., 1982). This has been 
shown in several ways. First, there was a marked increase 
of the melting temperature of the drug-bound nucleic acid 
duplex. Second, drug-bound duplexes showed resistance to
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SI nucleases and snake venom phosphodiesterases. Third, 
CC-1065 bound to supercoiled plasmid DNA showed resistance 
to ethidium-induced unwinding. CC-1065 was able to 
displace netropsin, but netropsin was not able to displace 
bound CC-1065. Although CC-1065 was originally known to 
bind preferentially to double-stranded DNA, it was also 
capable of binding to the certain RNA-DNA or triple­
stranded nucleic acids (Krueger et al., 1985). It was 
deduced that CC-1065 can bind to certain RNA-DNA hybrids or 
triple-helixes which are B-form or have a groove 
characteristic of B-form nucleic acid.
Structurally, CC-1065 is composed of two identical 
benzodipyrrole subunits and third subunit with an active 
cyclopropane ring connected to pyrroloindole system (Fig.
1). An X-ray crystallographical study by Chidester et al. 
(1981) demonstrated that CC-1065 has right-handed twist or 
pitch along the long axis of the drug, giving it a banana­
like shape with a convex and a concave side. These 
structural characteristics provide for an excellent fit of 
the drug molecule into the minor groove with the 
hydrophobic portion facing the inside edge of the minor 
groove and the hydrophilic groups aligning along the 
outside edge (Chidester et al., 1981). The minor groove 
binding feature of CC-1065 was further demonstrated by the 
nuclear magnetic resonance and spectroscopic studies by
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Scahill et al. (1990) using CC-1065 bound to an oligomer 
duplex.
By treating the CC-1065-DNA adduct for 30 min at 
100°C, a CC-1065-adenine adduct could be released which was 
extracted into butanol (Hurley et al., 1984; Reynolds et 
al., 1985). Because the drug-adenine adduct was thermally 
labile, this method was used to determine its sequence 
specificity in DNA. Using single end-labeled fragment of 
SV4 0 early promoter it was found that CC-1065 had high 
sequence specificity (Hurley et al., 1984; Reynolds et al.,
1985). The consensus sequences were 5-'AAAAA and 5'-PuNTTA 
(Pu indicates purine; N indicates any base) and the 3 '-A 
was alkylated by CC-1065 in each case.
Electronic absorption and circular dichroism (CD) 
studies of CC-1065 interaction with poly(dA)-poly(dT) 
suggested that van der Waals interactions may influence the 
alignment of CC-1065 in the minor groove to help direct the 
site of covalent bond formation (Krueger et al., 1986). A 
local asymmetric conformational change, which extended more 
than one helix turn to the 5' side of covalent binding 
site, occurred on the DNA strand that was covalently bound 
to CC-1065 (Hurley et al., 1987). Hurley et al. (1988) 
suggested that the sequence-specific covalent adduct 
formation was not affected by noncovalent interactions of 
the B- and C-subunits of CC-1065 but was by a sequence- 
dependent reactivity of the adenine at the alkylating
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
4 8
subunit. However, this is not based on experimental data 
and this concept has been disputed by Boger et al. (1990;
1991). The binding mechanism of the drug was suggested by 
Kopka et al. (1985) and Krueger et al. (1986) to occur as 
follow. First, CC-1065 binds to the minor groove through 
van der Waals interactions accompanied by entropic release 
of water molecules in the minor groove. The drug probably 
fits the groove at an optimal distance and geometry such 
that N3 of the adenine and the methylene carbon of the 
cyclopropane ring come together for covalent bond 
formation.
Lin et al. (1991) proposed that bridging of the 
phenolic proton at the alkylating subunit of the CC-1065 to 
the anionic oxygens on the phosphate on the noncovalently 
modified DNA strand by an intervening water molecule can 
provide additional stabilization of the drug binding, but 
the experimental evidence for this is completely lacking 
and the acid-catalyzed reaction proposed can not occur with 
a non-protonated DNA phosphate.
CC-1065 strongly inhibited the unwinding of DNA 
catalyzed by the dda protein of phage T4 and helicase II of 
Escherichia coli and may affect replication fork 
progression, DNA repair, or homologous recombination (Maine 
et al., 1992). Sun et al. (1992) found that CC-1065 and 
its analogs were able to inhibit the progression of Klenow 
fragment, E. coli polymerase, and T4 DNA polymerase
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probably by inhibiting base pairing around the drug 
modification site rather than by blocking the polymerase 
binding. Using a viral DNA-E. coli transfection system, 
Tang et al. (1988) showed that UVRABC nucleases, which are 
normally involved in repairing UV light-induced DNA damage, 
were also capable of repairing the CC-1065-DNA adduct.
They showed that the UVRABC nucleases incised the eighth 
phosphodiester bond to the 5' side of the CC-1065 binding 
site only on the drug-modified strand but not the opposite 
strand.
Numerous chemically synthesized analogs of CC-1065 
have been developed (Wierenga, 1981; Warpehoski et al., 
1986; Kelly et al., 1987; Warpehoski et al., 1988; Mitchell 
et al., 1989; Li et al., 1991). These analogs were 
designed to maintain strong antitumor activity against a 
broad spectrum of cancer cell lines like CC-1065, without 
the overt host toxicity observed in the parent compound. 
Among them U-73,975 and U-77,779 are under phase I clinical 
trial or preclinical toxicologic evaluations, respectively.
The binding and cytotoxicity of the enantiomers of 
bis-indole analogs of CC-1065 by Warpehoski et al. (1988) 
demonstrated that the analog with the same stereochemical 
configuration of that of CC-1065 showed better DNA binding, 
hyperstabilization, and cytotoxic activity compared to its 
enantiomer. Swenson et al. (1988) found that the analogs 
preferred to bind AT-rich sites in the minor groove of DNA
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with a similar sequence-specificity to that of CC-1065.
This demonstrated that the sequence-specificity of the drug 
might be more dependant upon the DNA structure than on the 
drug molecule itself. Mitchell et al. (1989) synthesized a 
series of alkylating subunit (CPI) analogs which have two 
alkylating subunits that were linked by a flexible length 
of methylene chain. Those CPI analogs cross-linked the DNA 
as evidenced by alkaline agarose gel electrophoresis. 
Several of these analogs showed more potent antitumor 
activity, both in vivo and in vitro, than CC-1065.
U-73,975 were effective against a broad spectrum of murine 
and human tumors, and moderately effective against highly 
drug-resistant pancreatic 02 carcinoma; however, U-73,975 
did not cause delayed death in non-tumor bearing mice (Li 
et al., 1991).
CC-1065 and its analogs bound to chromatin in a manner 
similar to that of calf thymus DNA but the intensity of the 
induced CD spectra and the rate of irreversible covalent 
bond formation with calf thymus DNA was stronger than that 
with chromatin (Moy et al., 1989). CC-1065 bound very
weakly or nonspecifically to histone proteins. 
Interestingly, the binding of CC-1065 to chromatin was 
mainly reversible after 24 hr incubation, while the 
interaction with calf thymus DNA was irreversible shortly 
after incubation. The conformation of DNA in chromatin is 
different from that of naked DNA due to interactions with
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histone and non-histone proteins. This in turn can 
significantly affect the binding accessibility of the CC- 
1065. Further research in this area would be important for 
understanding the action of this drug at the cellular 
level.
Bhuyan et al. (1992) found that CC-1065 was most toxic 
to the cells in mitosis but U-73,975 showed strong activity 
against cells in G1 to early S phase. The reason for this 
phenomenon was not well-understood but was speculated that 
it may be due to differences in cellular uptake or DNA 
repair response to bound CC-1065 and U-71,184. The 
concentration of U-73,975 required to inhibit DNA synthesis 
was 10-fold higher than that required to inhibit the growth 
of L1210 tumor cells. Based on the above and on Lee and 
Gibson's findings (1991), Bhuyan et al. (1992) proposed 
that U-73,975 may alkylate chromatin at a specific 
susceptible site rather than inhibiting DNA synthesis. 
Biological activity of both CC-1065 and its analogs can be 
affected by different alkylating sites and DNA repair 
mechanism present in different cells.
The applicability of the large number of CC-1065 
analogs to the current project remains to be determined.
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CHAPTER II. BINDING OF CC-1065 AND U-71,184 TO 
SENSE-ANTISENSE DUPLEXES
Introduction
Antisense oligonucleotides are short pieces of 
synthetic, single-stranded oligodeoxyribonucleotiaes often 
containing chemical modifications (Ulman and Peyman, 1990). 
The basic concept behind development of antisense 
oligonucleotides is that they can hybridize to 
complementary regions of target mRNA and inhibit 
translation and processing of specific mRNA. Translation 
arrest appears to be due to two major mechanisms. First, 
the oligonucleotides may mask the attachment sites for 
ribosomes (Blake et al., 1985; Boiziau et al., 1991) and 
second, duplexes formed with mRNA cause activation of RNase 
H, a ubiquitous enzyme that digests RNA from RNA-DNA 
duplexes (Walder and Walder, 1988). Antisense 
oligonucleotides can also interfere with several mRNA 
processing steps such as splicing (Volloch et al., 1991a), 
5'-capping (Bacon and Wickstrom, 1991), and reverse 
transcription of the retroviral mRNA (Boiziau et al.,
1992).
Antisense oligonucleotides have been widely used to 
selectively inhibit the expression of specific oncogenes 
(Wickstrom et al., 1988; Calabretta et al., 1991; Chang et 
al., 1991; Hara et al., 1991), viral genes (Smith et al., 
1986; Matsukura et al., 1989; Goodarzi et al., 1990;
Cowsert et al., 1993), and to kill parasites (Verspieren et
52
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al., 1987; Rapaport et al., 1992) in cell culture systems. 
Several experimental cancer therapies using antisense 
oligonucleotide strategies in whole animals have been 
reported recently (Whitesell et al., 1991; Ratajczak et 
al., 1992b; Wickstrom et al., 1992). Thus exogenous 
antisense oligonucleotides have drawn much interest 
recently as potential antiviral or anticancer agents 
(Reynolds, 1992).
To exert their optimal therapeutic efficacy, antisense 
oligonucleotides must meet three important criteria (Stein 
and Cheng, 1993). First, they should be stable in 
biological systems. Second, the oligonucleotides should 
be capable of entering cells and remain in the target cells 
long enough to show significant biological effects. Third, 
they should duplex with target mRNA with high specificity 
and stability.
Oligonucleotides with phosphodiester bonds are highly 
susceptible to nucleases, especially 31-exonucleases, and 
have short half-lives in serum or media (Wickstrom, 1986; 
Tidd and Warenius, 1989). Thus oligonucleotides with 
phosphodiester bonds would likely need to be administered 
in high doses, which in turn may cause nonspecific 
inhibition of translation and other cell functions 
(Cazenave et al., 1989; Chang et al., 1989; Woolf et al.,
1992). Numerous chemical modifications have been directed 
toward the phosphate atom or sugar moiety to overcome the
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nuclease susceptibility of the oligonucleotides in 
biological systems. Of the modified phosphodiester 
structures, phosphorothioates (Stec et al., 1984; Zon and 
Geiser, 1991) and methylphosphonates (Miller et al., 1981; 
Miller et al., 1986) are most commonly used. 
Oligonucleotides with a-anomeric configurations have also 
been used (Morvan et al., 1987a; Morvan et al., 1991).
A consequence of internucleotide bond modification is 
the reduction in duplex stability between antisense 
oligonucleotides and mRNA, possibly due to the occurrence 
of diastereoisomers (R and S) at phosphate atoms. The 
diastereoisomers may affect the geometrical conformation 
and consequent base pairing stability in the duplex (Maher 
and Dolnick, 1988; Stein et al., 1988b). Various 
strategies to overcome the loss of duplex stability due to 
phosphodiester bond modifications have been considered, 
including attachment of intercalating (Asseline et al., 
1984a; Zerial et al., 1987) or alkylating (Vlassov et al., 
1988) agents to the antisense stand. Of these strategies, 
intercalating agents appear to have the best success with 
increases in duplex melting temperature of as much as 15°C 
(Asseline et al., 1984a). Another approach to enhancing 
stability of the duplexes was suggested by minor-groove 
binding ligands such as CC-1065 that are known to increase 
the stability of the DNA duplex (Li et al., 1982; Swenson 
et al., 1982).
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CC-1065 (Fig. 1), a fermentation product of 
Streptomvces zelensis. binds strongly to the AT-rich sites 
of the minor groove of duplex DNA and other B-form nucleic 
acids (Swenson et al., 1982; Krueger et al., 1985). When 
bound, CC-1065 appears to hyperstabilize duplex DNA, as 
shown by the marked increase of the melting temperature, 
increased resistance to nucleases, and inhibition of the 
intercalative unwinding of supercoiled DNA (Swenson et al., 
1982) . The ability of this class of agent to bind and 
stabilize other types of duplexes is unknown. If CC-1065 
can bind and stabilize RNA-DNA duplexes with phosphodiester 
bond modifications, it can be a good model ligand for 
tethering to antisense oligonucleotides to improve their 
efficacy.
This study was conducted to determine if the minor 
groove-binding ligands such as CC-1065 and its analog, 
U-71,184 (Fig. 1), can bind to oligonucleotide duplexes in 
which one strand has modified internucleotide bonds. Of 
further interest was whether CC-1065 and U-71,184 could 
bind to RNA-DNA oligonucleotide duplexes in which the DNA 




CC-1065 and U-71,184 were gifts from the Upjohn Co., 
Kalamazoo, MI. Aliquots of CC-1065 and U-71,184 were
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dissolved in dimethyl formamide (DMF) (Sigma Chemical Co., 
St. Louis, MO) to make concentrated stocks, which were then 
stored at -20°C. Fresh stocks were prepared every 3 
months. The NACS-52 columns were acquired from Bethesda 
Research Laboratories, Bethesda, MD. All other reagents 
and solvents were analytical grade or better.
Synthetic Oligonucleotides
The target (sense) sequence for these studies was a 
20-base (20 mer) sequence chosen from a 5' upstream region 
of the envelope gene of the equine infectious anemia virus 
(EIAV). The sequences used in this study and their 
compositions are stated in Table 1. Sequence 1 (SI), 
sequence 3 (S3), sequence 6 (S6), and sequence 7 (S7) were 
synthesized by Gene Lab (Louisiana State University) on an 
automated DNA synthesizer (Cruachem PS250, Sterling, VA) 
using cyanoethyl phosphoramidite chemistry. The sequence 4 
(S4) and sequence 5 (S5) were obtained from American 
Synthesis, Pleasanton, CA. Sequence 2 (S2) was purchased 
from National Biosciences, Plymouth, MN. The S2 and S5 
were not purified prior to use and were approximately 3 0% 
pure, the remainder being truncation sequences. Salmon 
sperm DNA and poly rA (S8) were purchased from Sigma 
Chemical Co., St. Louis., MO.
Drug Binding to Duplexes
Duplexes were formed with 3.7 5 nmol (which is 
equivalent to 75 nmol nucleotides for a 20-mer) each of SI

















Table 1. Composition and Sequence of the Synthetic Oligonucleotides.
Seq. # Type Bond* Lenghts Sequence
SI DNA PO 20 51-TTACTTCAGTTATGAGACCA-3'
S2 RNA PO 20 Same as Seq. 1
S3 DNA PO 20 5'-TGGTCTCATAACTGAAGTAA-3'
S4 DNA PS 20 Same as Seq. 3
S5 DNA MP 20 Same as Seq. 3
S6 DNA PO 20 5'-AAAAAAAAAAAAAAAAAAAA-3'
S7 DNA PO 20
S8 RNA PO POLYMER Poly rA
a Nomenclature used here is PO for normal phosphodiester bond, PS for 100% 
phosphorothioate in the internucleotide bond, and MP for 100% methyl phosphonate internucleotide bond.
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and S3 (duplex 1), with SI and S4 (duplex 2), with SI and 
S5 (duplex3), with S2 and S3 (duplex 4), with S2 and S4 
(duplex 5), with S6 and S7 (duplex 6), and with S6 and S8 
(duplex 7) in 0.36 ml of 0.01 M sodium cacodylate buffer,
1 mM EDTA, pH 7.2 (Table 2). These samples were incubated 
with CC-1065 or U-71,184 in 0.04 ml of DMF for 4 hr at 
37°C. The final amount of CC-1065 in the reaction ranged 
from 0 to 15 nmol. Duplexes 3, 4, and 5 were formed by 
incubating with 3-fold excess of S2 and S5 to ensure duplex 
formation. For reactions in which U-71,184 was used 
instead of CC-1065, the final amount of U-71,184 in the 
reaction was 15 nmol. For single strand binding studies, 
3.75 nmol of S3, S4, and S5 were incubated with 15 nmol of 
CC-1065 or U-71,184 as described.
After 4 hr incubation, nucleic acids were isolated 
from the unbound drug by ethanol precipitation followed by 
washing twice in ice-cold 70% ethanol (Swenson et al.,
1982). An alternative method to remove the unbound drug 
was using NACS-52 anion-exchange columns. After 
incubation, the reaction mixture was applied to NACS-52 
columns which were washed with 0.01 M sodium cacodylate 
buffer, 1 mM EDTA, 0.1 M NaCl, pH 7.2. Nucleic acids were 
eluted from the columns with 1 ml of 0.01 M sodium 
cacodylate buffer, 1 mM EDTA, 1 M NaCl, pH 7.2. The 
unbound drug adhered strongly to the NACS-52 matrix and 
could not be eluted even with extensive washing with the
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Table 2. Composition of Duplexes.
Duplex # Composition Length
1 SI - S3 20-mer
2 SI - S4 20-mer
3 SI - S5 20-mer
4 S2 - S3 20-mer
5 S2 - S4 20-mer
6 S6 - S7 20-mer
7 S6 - S3 polymer
Table 3. Binding of CC-1065 to Salmon Sperm DNA.
Initial CC-l065/Nucleotidea CC-1065 Bound/Nucleotideb
0.005 0.004 ± 0.0006
0.01 0.007 ± 0.0006
0.015 0.012 ± 0.002
0.020 0.013 ± 0.0006
0.025 0.017 ± 0.001
0.030 0.019 ± 0.0006
0.034 0.021 ± 0.001
0.04 0.024 ± 0.0006
a Indicates number of CC-1065 initially incubated per 
nucleotide of salmon sperm DNA. 
b Indicates number of CC-1065 bound after incubation.
The values are presented as mean ± standard deviations
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
6 0
buffer. Equivalent results were obtained by either the 
ethanol precipitation or the NACS-52 methods.
Measurement of Drug Binding
The amount of CC-1065 and U-71,184 bound to the 
recovered nucleic acids was calculated from A260 (nucleic 
acids) and A365 (drug chromophore) ratio as previously 
described (Swenson et al., 1982). Extinction coefficients 
of 48,000 for CC-1065 and 32,000 for U-71,184 were used 
(Warpehoski et al., 1988) and the extinction coefficients 
for the oligonucleotides were individually calculated by 
nearest-neighbor approximation (Fasman, 1975). The average 
base molar extinction value of 6,500 for salmon sperm DNA 
was used (Sewnson et al., 1982).
Results
CC-1065 bound to duplex 6 in a dose-dependent manner. 
The binding was saturated at about 2.5 drug molecules per 
duplex 6 (Table 4). Binding of CC-1065 to salmon sperm DNA 
also revealed a highly dose-dependent fashion. One CC-1065 
molecule bound every 40 nucleotides of salmon sperm DNA 
when incubated at an initial ratio of 1 drug per 25 
nucleotides in the reaction (Table 3). CC-1065 also bound
to duplex 1 in a highly dose-dependent manner (Table 4). 
Approximately one CC-1065 molecule bound to the duplex 1 
when the duplex was initially incubated with 1 and 1.6 drug 
molecules per duplex and the binding was saturated at about 
2 drug molecules per duplex. The binding of CC-1065 to

















Table 4. Binding of CC-1065 to DNA Duplexes as a Function of a Dose.
Final CC-1065 Bound in the Duplex
Initial D/Da Duplex 1 Duplex 2 Duplex 3 Duplex 6
0.4 0.36 ± 0.016 0.40 ± 0.00 Not Done 0.32 ± 0.04
1.0 0.84 ± 0.032 0.96 ± 0.02 0.64 ± 0.032 0.72 ± 0.024
1.6 1.20 ± 0.016 1.28 ± 0.04 Not done 1.12 ± 0.024
2.5 1.96 ± 0.04 1.88 ± 0.02 Not Done 2.32 ± 0.08
4 . 0 2.12 ± 0.08 1.96 ± 0.00 1.24 + 0.04 2.52 ± 0.08
a D/D indicates initial number of drug molecules incubated with duplex.
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duplex 2 revealed a dose-dependent response similar to that 
of duplex 1. However with duplex 3, the binding of CC-1065 
appeared to be limited to 1 drug molecule per duplex (Table 
4) •
U-71,184 bound to duplex 6 and saturated at 
approximately 2 drug molecules per duplex when an initial 
ratio of 4 drug molecules per duplex was used in the 
reaction (Table 5). The binding of U-71,184 to duplex 6 
was about 80% that of CC-1065. With duplex 1 or 2,
U-71,184 binding saturated at 1 drug molecule per duplex 
(Table 5), which is about half that of CC-1065. As with 
CC-1065, binding of U-71,184 to duplex 3 was limited to 1 
drug molecule per duplex (Table 5).
Both CC-1065 and U-71,184 were able to bind to duplex
7 in a dose-dependent fashion. The binding was saturated
at 1 drug molecule per duplex for both CC-1065 and U-71,184 
(Tables 5 and 6). The RNA sense strand (S2) was capable of 
binding CC-1065 when it was duplexed with either S3 or S4 
(refer to duplex 4 and 5) (Table 6). However, the binding 
affinity was about half that of DNA sense (SI) duplexed 
with S3 or S4 (refer to duplex 1 and 2) (Table 6).
The binding of CC-1065 and U-71,184 to single strands
of S3, S4, and S5 was not significant since less than 1
drug molecule per 200 base residues was bound when an 
initial ratio of one drug molecule per 10 nucleotides was 
applied (data not shown).
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Table 5. Comparative Binding of U-71,184 and CC-1065 
at Initial Drug/Duplex =0.1“.
Duplex # Bound U-71,184b Bound CC—1065b
1 1.04 ± 0.16 2.12 ± 0.08
2 1.04 ± 0.04 1.96 ± 0.00
3 1.16 ± 0.04 1.24 ± 0.04
6 1.96 ± 0.05 2.52 ± 0.08
7 0.94 ± 0.04 1.12 ± 0.04
a Drug/Duplex = 0.1 indicates that the duplexes were 
incubated with CC-1065 or U-71,184 at an initial 
ratio of 4 drugs per duplex in the reaction, 
b Averages ± standard deviations of drug molecules 
bound per duplex were presented.

















Table 6. Maximum Binding of CC-1065 to DNA-RNA Duplexes.





poly(rA) oligo (dT) 20 1
a Sense strand has the sequence of 5'-TTACTTCAGTTATGAGACCA-3', 
unless otherwise specified, 
b Antisense strand has the sequence of 3'-AATGAAGTCAATACTCTGGT-5', unless oterwise specified, 
c Initial CC-1065/duplex ratio in the reaction was 0.1, which is 
equivalent to 4 drug molecules per duplex. The results indicate 




Swenson et al. (1982) previously found that CC-1065 
bound strongly to calf thymus DNA and to AT polymers in a 
highly dose-dependent manner but bound only weakly to 
single-stranded nucleic acids and GC-containing polymers. 
The binding to target duplex was efficient, with about 85% 
of CC-1065 bound to calf thymus within a few minutes of 
incubation. The kinetics of interaction showed a rapid 
interaction of drug and DNA and no further binding occurred 
after 2 hr incubation. A CC-1065 analog, U-71,184, bound 
to calf thymus DNA and AT polymers and hyperstabilized the 
helix in a manner similar to that of CC-1065 (Swenson et 
al., 1988).
Our current binding study of CC-1065 against salmon 
sperm DNA was similar to that previously reported (Swenson 
et al., 1982). CC-1065 bound to salmon sperm DNA as to
calf thymus DNA in a similar dose-dependent manner (Table
3). Both CC-1065 and U-71,184 bound to duplex 6 also in a 
dose-dependent manner (Tables 4 and 5). The duplex 6 was 
saturated at approximately 2.5 and 2 drug molecules for 
CC-1065 and U-71,184, respectively.
CC-1065 is known to bind preferentially to B-form 
nucleic acids in a highly sequence-selective manner, with 
the consensus sequences of PuNTTA-3' (Pu=purine; N=any 
base) and AAAAA-31 (Hurley et al., 1984). U-71,184 also
appears to target similar sites (Swenson et al., 1988).
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There are two drug binding consensus sequences in the 20 
mer duplexes of sense and antisense strands. One is located 
at the center (AGTTA-3') of the target (sense) strand and 
the other is located at the 3'-end (AGTAA-3') of the 
antisense strand. Therefore, theoretically, up to two 
CC-1065 and U-71,184 molecules can bind to one 20-mer 
duplex at saturation.
Approximately two CC-1065 molecules were bound to 
duplex 1 and duplex 2 at saturation (Table 4). This 
indicates that CC-1065 was able to target both strong 
(sense strand) and weak (antisense strand) binding sites. 
However, the binding of CC-1065 to duplex 3 seems to be 
limited to 1 drug molecule per duplex at saturation (Table
4). It is likely that the consensus sequence in the 
methylphosphonate strand (S5) is not targeted by CC-1065.
In case of U-71,184 binding, the drug was saturated at one 
molecule per duplex regardless of phosphodiester bond 
modifications (Table 5). Again, it is likely that U-71,184 
was unable to target the binding sequence present on the 
antisense strand.
CC-1065 binds specifically to the minor groove of 
B-form DNA, typically DNA-DNA hybrids, however it can also 
bind to certain types of RNA-DNA hybrids or to triplex 
helices which can adopt a minor groove that mimics B-form 
nucleic acids (Krueger et al., 1985). X-ray crystallograpy 
(Chiedester et al., 1981) and nuclear magnetic resonance
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spectroscopic studies (Scahill et al., 1990) showed that 
CC-1065 has a right-handed twist and a banana-like shape 
which fits nicely into the minor groove of DNA.
Approximately one CC-1065 molecule was bound to an 
RNA-DNA (duplex 7) after an initial ratio of four drug 
molecules per duplex in the reaction (Table 6). The result 
is similar to that previously reported by Krueger et al. 
(1985). Interestingly, U-71,184 was also able to bind to 
duplex 7 at a saturation level similar to CC-1065 (Table
5). It has not been previously documented whether CC-1065 
can bind to RNA-DNA oligonucleotide duplexes with modified 
internucleotide linkage in the DNA strand. Our data 
clearly demonstrated that CC-1065 was able to bind to sense 
RNA (S2) duplexed with either S3 or S4 at 1 drug molecule 
per duplex (Table 6). It appears that only the binding 
sequence in the sense strand is targeted by CC-1065.
The minor groove of A-form nucleic acids (i.e. RNA 
duplex) may not provide a proper binding environment for 
CC-1065 in part due to 2'-OH groups present in the RNA 
strand which may sterically interfere with drug binding 
(Krueger et al., 1985). Also width and depth of the minor 
groove of A-form nucleic acids would likely be a poor site 
for interaction with CC-1065 and U-71,184 due to inadequate 
opportunity for van der Waals and other non-covalent 
interactions (Krueger et al., 1985).
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The RNA-DNA hybrid was conventionally thought to be in 
A-form, but Roberts and Crothers (1992) recently showed 
that DNA-RNA hybrids can exist as an intermediate of A- and 
B-forms and is not necessarily A-form only. The difference 
in the binding affinity of CC-1065 for oligo(dA)-oligo(dT) 
and poly(rA)-oligo(dT) is probably due to the final 
topology of the minor groove.
We found that CC-1065 and U-71,184 were able to bind 
to oligonucleotides composed of DNA—DNA or RNA-DNA 
duplexes. This binding occurred whether or not the 
phosphodiester bonds on the DNA strand were chemically 
modified. Since the minor-groove binding ligands are known 
to stabilize the duplex to which they are bound, our 
results strongly suggest that these ligands may be used to 
hyperstabilize the duplexes formed between mRNA and 
unmodified or phosphate-modified DNA antisense strands 
providing the duplex contains a drug binding sequence.
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CHAPTER III. HYPERSTABILIZATION OF SENSE-ANTISENSE 
DUPLEXES BY CC-1065 AND U-71,184
Introduction
Short lengths of synthetic single-stranded 
oligodeoxyribonucleotides and their chemically modified 
analogs, which are often referred to as antisense 
oligonucleotides, have been extensively utilized as a means 
to inhibit the expression of cellular genes (Neyses et al., 
1991; Wagner et al., 1992), oncogenes (Amini et al., 1986; 
Chang et al., 1991; Collins et al., 1992; Ratajczak et al., 
1992a) and virus replication (Agris et al., 1986; Smith et 
al., 1986; Matsukura et al., 1987; Goodarzi et al., 1990). 
The rationale for use of antisense oligonucleotides is that 
selection of appropriate sequences will permit these agents 
to form duplexes at specific sites on mRNA or pre-mRNA by 
normal Watson-Crick base pairing. Duplex formation can 
arrest processing and translation of mRNA and reverse 
transcription of retroviral mRNA by two major mechanisms. 
One is the activation of RNase H digestion of the target 
mRNA (Walder and Walder, 1988; Boiziau et al., 1992), and 
the other is steric masking of sequences involved in mRNA 
processing (Smith et al., 1986; Morvan et al., 1991) and 
translation initiation (Blake et al., 1985; Boiziau et al.,
1991).
While most works have been in vitro studies, sequence- 
dependent inhibition of tumor growth (Ratajczak et al., 
1992b; Georges et al., 1993), viral replication
69
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(Offensperger et al., 1993), and cellular gene expression 
(Simons et al., 1992) have also been shown to work in whole 
animals. Sufficient optimism has been generated that a 
phase 1 clinical trial of antisense oligonucleotides 
against myelogenous leukemia has already begun (Reynolds,
1992) and more trials are expected to be undertaken in the 
near future. As optimization of pharmacokinetics, 
pharmacodynamics and target selection progresses, antisense 
oligonucleotides will continue to show potential as 
therapeutic tools (Stein and Cheng, 1993).
Oligonucleotides with unmodified phosphodiester bonds 
have limited potential as therapeutic agents because of 
their biological instability (Wickstrom, 1986; Tidd and 
Warenius, 1989; Eder et al., 1991). This instability 
results primarily from nuclease attack. Various types of 
chemically modified antisense oligonucleotides have been 
developed to provide nuclease resistance and to enhance 
cellular uptake of oligonucleotides. The phosphodiester 
bond was the focus of most of the chemistry because of the 
many options for phosphate modifications offered by 
automated synthesis with phosphoramidite or phosphonate 
chemistries (Zon and Geiser, 1991). Examples of 
phosphodiester-modified structure analogs include 
methylphosphonates (Miller et al., 1981; Miller et al.,
1986), phosphorothioates (Stec and Zon, 1985), 
phosphorodithioates (Marshall et al., 1992), and
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phosphoramidates (Agrawal et al., 1988). Modifications at 
phosphorus have improved resistance of the oligonucleotides 
to nucleases (Agrawal and Goodchild, 1987; Stein et al., 
1988b), but have resulted in duplexes with target sequences 
that have lower duplex stability than those containing 
unmodified phosphodiester linkages. This was due in some 
cases to the formation of two distinct diastereoisomers at 
phosphate atom, which apparently affects the base-pairing 
stability of strands containing these modifications (Maher 
and Dolnick, 1988; Stein et al., 1988b; Lesnikowski et al., 
1990).
To enhance stability of duplexes containing strands 
with chemically modified internucleotide linkages, 
functional groups based on alkylating (Vlassov et al.,
1987), intercalating (Asseline et al., 1984a), and photo- 
activatable cross-linking agents (Lee et al., 1988) have 
been conjugated to oligonucleotides. These functional 
groups have shown variable potential as a means to promote 
duplex formation.
We have studied other agents known to stabilize 
nucleic acids duplexes as potential duplex-stabilizing 
ligands. Minor-groove binding agents, such as CC-1065 and 
U-71,184, were previously shown to hyperstabilize DNA 
duplexes (Swenson et al., 1982; Swenson et al., 1988), but 
much less has been determined about the ability of these 
agents to stabilize RNA-DNA duplexes. CC-1065 is a
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fermentation product of Streptomvces zelensis (Hanka et 
al., 1978). It is a potent antitumor antibiotic and its 
cytotoxicity may be due to hyperstabilization of cellular 
DNA and resultant inhibition of DNA synthesis (Li et al., 
1982; Swenson et al., 1982). Hurley et al. (1984) and 
Reynolds et al. (1985) found that CC-1065 binds selectively 
to the AT-rich sites of the minor groove of B-form nucleic 
acids in a sequence-selective manner. Until recently 
(Roberts and Crothers, 1992), it has generally been assumed 
that RNA-DNA hybrids were A-form. A-form duplexes do not 
appear to have a minor groove suitable for binding of 
CC-1065 (Krueger et al., 1985).
However, our recent studies showed that CC-1065 and 
U-71,184 were able to bind to 20-mer duplexes of DNA-DNA 
and RNA-DNA containing known CC-1065 binding sequences 
(Chapter 2). We also showed that CC-1065 and U-71,184 were 
able to bind to both DNA-DNA duplexes and RNA-DNA duplexes 
in which one strand has modified phosphodiester bonds.
This study was carried out to determine if bound 
CC-1065 and U-71,184 could hyperstabilize RNA-DNA duplexes 




CC-1065 and U-71,184 were gifts from the Upjohn Co., 
Kalamazoo, MI. The stock solutions of CC-1065 and U-71,184
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were prepared and stored as previously described (Chapter
2). The NACS-52 columns were purchased from Bethesda 
Research Laboratories, Bethesda, MD. Poly rA and 
distamycin A were obtained from Sigma Chemical Co., St. 
Louis, MO. Distamycin A solutions were made in methanol 
immediately before use. The synthetic oligonucleotides 
used in this study were synthesized or commercially 
obtained as described previously (Chapter 2).
Drug Binding to Duplexes
Duplexes containing CC-1065 and U-71,184 were prepared 
and purified by NACS-52 columns as previously described 
(Chapter 2). The duplex compositions are indicated in 
Table 7. Duplex-distamycin A solutions were formed directly 
in 0.36 ml of 0.01 M sodium cacodylate buffer containing 
1 mM EDTA and 1 M NaCl at pH 7.2, by incubating the 
duplexes with distamycin A in 0.04 ml of methanol for 4 hr 
at 37°C. These solutions were not purified by the NACS-52 
column. They were used directly for analysis because 
distamycin A, unlike CC-1065 and U-71,184, does not form 
covalent bonds with nucleic acids.
Thermal Melting Experiment
Melting temperatures (Tm) were measured as previously 
described (Li et al., 1982) using a Gilford 2400 UV/VIS 
spectrophotometer set at 260 nm. The spectrophotometer was 
equipped with a Peltier-based Thermoset controller that was 
modified for temperature programming. Four samples were

















Table 7. Composition of Duplexes and Base Tm.
Duplex # Sense Type,,b Antisense Typea,c Duplex Length Tm (°C)d
1 oligo(dA)20 oligo(dT)20 2 0-mer 57
2 poly(rA) oligo (dT) 20 polymer 50
3 DNA-PO DNA-PO 20-mer 68
4 DNA-PO DNA-PS 20-mer 64
5 DNA-PO DNA-MP 20-mer 51
a Nomenclature used here is PO for normal phosphodiester bonds, PS for 100% 
phosphothioester bonds, and MP for 100% methylphosphonate bonds, 
b Sense strand has the sequence 5'-TTACTTCAGTTATGAGACCA-3', unless 
otherwise specified, 
c Antisense strand has the sequence 3'-AATGAAGTCAATACTCTGGT-5', unless otherwise specified, 
d Mean of the melting temperature of each duplex measured in 0.01 M sodium 
cacodylate buffer, 1 mM EDTA, 1 M NaCl pH 7.2.
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analyzed per single run. The sample temperature was 
increased at a rate of 0.5°C per min from 20°C to 95°C.
A260 values were digitalized (12-bit) and the data were 
analyzed with Lotus 1-2-3 (Lotus Development Corporation, 
Cambridge, MA) and SigmaPlot (Jandel Scientific, San 
Rafael, CA) software. A total of 150 data points were 
collected from each run. The Tm is taken as the 
temperature at the midpoint of the absorption curve. All 
the studies were done in triplicate and were statistically 
analyzed by Student's t-test and considered significant if 
P<0.05.
Results and Discussion
As described before (Swenson et al., 1982; Swenson et 
al.,1988), CC-1065 and U-71,184 bound to 20-mer AT oligomer 
in a dose-dependent manner and were saturated at 2.5 and 2 
molecules of CC-1065 and U-71,184 per duplex, respectively 
(Chapter 2). The previous melting temperature study of AT 
polymer demonstrated that Tm of the AT polymer was 
increased about 43°C and 25°C when it was bound with 
CC-1065 and U-71,184, respectively (Swenson et al., 1988).
Base Tm of duplexes with no drug bound is presented in 
Table 7. The duplex 1 (oligo(dA)20-oligo(dT)20) when 
saturated at 2.5 molecules of CC-1065 or 2 molecules of 
U-71,184 per duplex, showed increase in Tm of 31°C (Table 
8) and 27°C (Table 9), respectively. Our results differ 
slightly from that of previous work by Swenson et al.
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Table 8. Effect of CC-1065 on the Thermal Melting 
Temperature of DNA Duplexes.




2 1 28 °C
3 2 17 °C
4 2 20 °C
5 1 21 °C
a Indicates numbers of CC-1065 bound to each duplexes 
after incubation at an initial ratio of 4 drug 
molecules/duplex in the reaction, 
b The a Tm was determined by substracting the base 
Tm (Table 7) from Tm of duplex-CC-1065. 
c The results were significantly different from base 
Tm by Student's t-test (P<0.05).
Table 9. Effect of U-71,184 on Duplex Separation 
Temperature.




2 1 2 °C
3 1 7 °C
4 1 9 °C
5 1 20 °C
a Indicate numbers of U-71,184 bound to each
duplexes after incutation at an initial ratio of 
4 drug molecules/duplex in the reaction, 
b The a Tm was determined by substracting the base 
Tm (Table 7) from the Tm of U-71,184-duplex, 
c The results were significantly different from base 
Tm by Student's t-test (P<0.05) except duplex 2.
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(1938). It is likely due to difference in conditions of 
analysis such as the use of 1 M NaCl or AT oligomer rather 
than polymer in our analyses. Distamycin A, which has been 
reported to stabilize poly(dA)-poly(dT) (Zimmer et al., 
1972), was also capable of stabilizing duplex 1 as shown by 
a 21°C increase in Tm after an initial ratio of 4 molecules 
of distamycin A per duplex in the reaction (Table 10).
We have shown that both CC-1065 and U-71,184 were able 
to bind to duplex 2 (poly (rA)-oligo (dT) 20) . The bindings of 
the drugs occurred in a dose-dependent manner and saturated 
at approximately 1 molecule of CC-1065 and U-71,184 per 
duplex (Chapter 2). Comparative study of the effects of 
the three different ligands on the stability of duplex 2 
revealed that only CC-10656 was capable of strongly 
stabilizing duplex 2 as shown by the increase in Tm by 28°C 
(Table 8). This can be compared to the effects of U-71,184 
(Table 9) and distamycin A (Table 10) which have increased 
the Tm of 2°C by 4°C, respectively.
Structurally, U-71,184, like distamycin A, lacks 
methylene rings and the oxygenated functions present in 
CC-1065. It is likely that the negligible stabilizing 
effect of these agents against the RNA-DNA duplexes is due 
to reduced opportunities for van der Waals and 
electrostatic interactions with the minor groove of the 
duplex. Boger et al. (1990) suggested that the methylene 
rings and the oxygenated functions are important in the
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Table 10. Effect of Distamycin A on Melting 
Temperature of Duplexes*.
Duplex # a Tmb
1 21.3 °C
2 4.0°C
3 o • o O
4 1.5 °C
a Indicates melting temperature of duplexes 
when they were incubated with distamycin 
at an initial ratio of 4 molecules of 
distamycin per duplex in the reation 
b a Tm was determined by substracting the 
base Tm (Tab. 7) from the Tm of the 
duplexes bound with distamycin.
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minor-groove binding affinity of CC-1065 and its analogs. 
Kopka et al. (1985) showed that the binding and sequence 
selectivity of distamycin A is due to van der Waals 
interactions between the drug and the binding sites in the 
minor groove and was not due to hydrogen bonding. A 
similar process presumably occurs for U-71,184 and CC-1065 
(Krueger et al., 1986).
Previous studies by Swenson et al. (1982) showed that 
the Tm of calf thymus DNA was increased about 30°C when it 
was bound with CC-1065 at a CC-1065/nucleotide ratio of 
1:7. U-71,184 was also capable of increasing the Tm of
calf thymus DNA; however, the stabilizing effect of 
U-71,184 was about 70% that of CC-1065 (Swenson et al., 
1988). As we described in Chapter 2, CC-1065 and U-71,184 
were able to bind to duplexes 3, 4, and 5, which contain a 
potential drug binding sub-sequence and have a modified 
phosphodiester bond on one DNA strand.
Duplex 3 (20-mer DNA duplex in which both strands were 
made with phosphodiester bonds) has a known high affinity 
binding site, 5'-AGTTA-3' on the sense strand and a lower 
affinity site, 5'-AGTAA-3' at the 3' end of the antisense 
strand (Reynolds et al., 1985). When duplex 3 was 
saturated at 2 drug molecules per duplex, the Tm of duplex 
3 was increased by about 17°C (Table 8), while binding of 1 
drug molecule per duplex increased the Tm by 13°C. 
Apparently CC-1065 can bind to the second binding site
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present at the 3' end of the antisense strand, but the 
effect of this binding minimally contributes to 
hyperstabilize the duplex. Binding of one U-71,184 to 
duplex 3 was capable of increasing the Tm of the duplex by 
only 7°C (Table 9) which is about half that of CC-1065. 
Distamycin A increased the Tm of duplex 3 by only 1°C 
(Table 10).
The binding of CC-1065 and U-71,184 with duplex 4 
(20-mer DNA duplex with phosphorothioate-based antisense 
strand) was similar to that with duplex 3 (Chapter 2). The 
binding was dose-dependent and saturated at 2 and 1 
molecules of CC-1065 and U-71,184 per duplex, respectively. 
Duplex 4, when saturated with CC-1065, showed about a 20°C 
increase of Tm, which was about 3°C higher than that seen 
with duplex 3 (Table 8). As with duplex 3, the Tm of 
duplex 4 was increased only 9°C when it was saturated with 
U-71,184 (Table 9). From these results it is apparent that 
the oligonucleotide with phosphorothioate linkages can 
function nearly identically to phosphodiester 
oligonucleotides with regard to binding and duplex 
stabilization effects of CC-1065 and U-71,184.
Only one drug molecule of CC-1065 and U-71,184 was 
bound to duplex 5 (20-mer DNA with methylphosphonate based 
antisense strand) at the highest binding level achieved 
(Chapter 2). The hyperstabilizing capability of U-71,184 
against duplexes 3 and 4 was only half that of CC-1065, but
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with duplex 5, it was as effective as CC-1065 (Table 9). 
Presumably, increased van der Waals interactions between 
U-71,184 and methyl groups of methylphosphonates may have 
promoted the hyperstabilization effect of U-71,184 against 
duplex 5. Further studies using NMR (Scahill et al., 1990) 
or X-ray crystallogrgaohy (Kopka et al., 1985) will be 
needed to evaluate this speculation.
The results of our Tm studies of duplex 1 with CC-1065 
and U-71,184 are in general agreement with previous work 
(Swenson et al., 1988). We have demonstrated that both 
CC-1065 and U-71,184 were able to stabilize 20-mer DNA-DNA 
duplexes in which one strand was modified with 
phosphorothioate and methylphosphonate internucleotide 
bonds. The effects of CC-1065 and U-71,184 on Tm of RNA- 
DNA duplex have not been reported previously.
Kopka et al. (1985), Boger et al. (1990), and Krueger 
et al. (1986) have stressed the importance of van der Waals 
interactions in binding of CC-1065 and U-71,184 to the 
minor groove of DNA duplexes. The ability of U-71,184 to 
bind and stabilize duplexes containing methylphosphonate 
internucleotide linkage is consistent with the perceived 
role of this type of molecular bonding in the binding of 
CC-1065-like ligands to nucleic acids.
In conclusion, only CC-1065 could stabilize both 
duplexes comprised of DNA-DNA or RNA-DNA. Furthermore, the 
stabilization occurred in DNA duplexes in which one strand
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was modified with phosphorothioate or methylphosphonate 
bond. While further work is needed to fully characterize 
the effects of these ligands on the duplexes, the present 
study suggests that the drugs studied should yield 
increased stabilization for DNA-RNA duplexes in general.
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CHAPTER IV. EFFECT OF CC-1065 AND AN ANTISENSE 
OLIGONUCLEOTIDE ON IN VITRO TRANSLATION OF AN 
mRNA DERIVED FROM EQUINE INFECTIOUS ANEMIA VIRUS
Introduction
Since synthetic oligonucleotides (antisense) were 
first used by Zamecnik and Stephenson to inhibit the 
replication of Rous sarcoma virus (1978), antisense 
oligonucleotides have been widely used as tools to 
selectively inhibit gene expression (Ulman and Peyman,
1990). The rational basis of antisense oligonucleotide 
technology is that hybridization of oligonucleotides 
(antisense) to complementary (sense) regions of mRNA will 
disrupt processing and translation of the mRNA. Antisense 
oligonucleotides appear to exert their function by two 
major mechanisms. First, by forming duplexes with mRNA, 
antisense oligonucleotides can sterically mask the binding 
sites for ribosomes and inhibit translation initiation 
(Miller and Ts'o, 1987; Boiziau et al., 1991). Second, 
duplex formation by antisense oligonucleotides may activate 
RNase H, which digests RNA of RNA-DNA duplex (Walder and 
Walder, 1988; Boiziau et al., 1992).
Although, in cell culture systems, antisense 
oligonucleotides have shown activity against oncogenes 
(Amini et al., 1986; Yu et al., 1989; Catlett et al., 1991) 
and viral genes (Agris et al., 1986; Smith et al., 1986; 
Matsukura et al., 1987; Cowsert et al., 1993), it has long 
been appreciated that potential in vivo applicability would
83
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be significantly limited by the instability of 
phosphodiester—based oligonucleotides in biological systems 
(Wickstrom et al., 1986; Tidd and Warenius, 1989; Eder et 
al., 1991). There have been considerable efforts in 
medicinal chemistry to overcome the instability of 
antisense oligonucleotides, resulting in development of 
numerous structurally modified oligonucleotides with 
enhanced stability (Cook, 1991). Among the modified 
structures, phosphorothioates (Stec et al., 1984; Zon and 
Geiser, 1991) and methylphosphonates (Miller et al., 1981; 
Miller et al., 1986) are the two most commonly used. These 
modified structures become more resistant to endo- and 3'- 
or 5’-exonucleases than the oligonucleotides with 
phosphodiester bonds (Agrawal and Goodchild, 1987; Stein et 
al., 1988b).
Replacement of phosphodiester bonds in an antisense 
oligonucleotide with phosphorothioates and 
methylphosphonates results in reduced stability of 
antisense-mRNA duplexes (Stein et al., 1988b; Maher and 
Dolnick, 1988; Lesnikowski et al., 1990). To overcome the 
reduced duplex stability, antisense oligonucleotides with 
tethered ligands such as intercalating (Asseline et al., 
1984a; Zerial et al., 1987) and photoactivatable cross- 
linking (Lee et al., 1988) agents have been developed. The 
initial findings with these ligands indicated the potential 
usefulness of the concept.
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Results from our studies (Chapters 2 and 3) and others 
(Swenson et al., 1982; Kruegr et al., 1985) suggested that 
helix-stabilizing, minor-groove binding agents such as CC- 
1065 might be ideal ligands to tether to antisense 
oligonucleotides to enhance stability of nucleic acid 
duplexes. We hypothesized that, by tethering to antisense 
oligonucleotides, CC-1065 could be specifically delivered 
to a mRNA target and create a non-displaceable patch of 
duplexed oligonucleotide on the mRNA. Target mRNA 
sequences can be selected to include known CC-1065 binding 
sub-sequences (Reynolds et al., 1985).
This study was conducted to determine if CC-1065 and a 
20-mer DNA antisense oligonucleotide directed against the 
env and S2 genes of equine infectious anemia virus (EIAV) 
could inhibit translation of that sequence.
Materials and Methods 
Synthetic Oligonucleotides and Plasmid pSP585
The antisense oligonucleotide used in this study was a 
20-base sequence complementary to the env and S2 genes of 
EIAV and had a sequence of 51-TGTTGGGTAATAGGGGTTGA-3' (Fig.
2). A 20-mer sense oligonucleotide with a sequence of 
5'-TCAACCCCTATTACCCAACA was made as control. Both sense 
and antisense oligonucleotides were synthesized by the Gene 
Lab (Dr. K. G. Kousoulas, Louisiana State University). The 
plasmid pSP585 was kindly provided by Dr. Ding S. Shih, 
Department of Biochemistry, Louisiana State University.


















401 CAGAGGAGAA CUUACAGAAG UCUUCUGGAG GUGUUCCUGG CCAGAACACA
451 GGAGGACAG 513 5 GAAGCA AGACCCAACU
5151 ACCAUUGUCA GCUGUGUUUC CUGAGGUCUC UAGGAAUUGA UUACCUCGAU
5201 GCUUCAUUAA GGAAGAAGAA UAAACAAAGA CUGAAGGCAA UCCAACAAGG
S2 start5251 AAGACAACCU CAAUAUUUGU UAUAAGGUUU GAUAUAUGGG AUUAUUUGGUenv start
5301 AAAGGGGUAA CAUGGUCAGC AUCGCAUUCU AUGGGGGGAU CCCAGGGGGAAntisense Taraet
5351 AUCUCAACCC CUAUUACCCA ACAGUCAGAA AAAUCUAAGU GUGAGGAGAA
5401 CACAAUGUUU CAACCUUAUU GUUAUAAUAA UGACAGUAAG AACAGCAUGG
5451 CAGAAUCGAA GGAAGCAAGA GACCAAGAAA UGAACCUGAA AGAAGAAUCU
5501 AAAGAAGAAA AAAGAAGAAA UGACUGGUGG AAAAUAGGUA UGUUUCUGUU
5551 AUGCUUAGCA GGAACUACUG GAGGAAUACU UUGGUGGUAU GAAGGACUCC
5601 CACAGCAACA UUAUAUAGGG UUGGUGGCGA UAGGGGGAAG AUUAAACG GA
5651 UCUGG
Fig. 2. Sequence of mRNA Translated
coos
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The plasmid pSP585 was constructed by inserting a 585 base 
proviral DNA segment of EIAV into the multiple cloning site 
of the pSP65 plasmid (Promega Biotec Co., Madison, WI).
The plasmid pSP585 contains open reading frames for the 
env and S2 proteins.
In Vitro Transcription of pSP585 Plasmid
Transcripts were made from the pSP585 plasmid by SP6 
RNA polymerase using the Megascript in vitro transcription 
kit (Ambion, Austin, TX) according to the manufacturer's 
recommendation. The incubation mixtures were composed of 5 
mM of ATP, CTP, UTP, 1 mM GTP, 4 mM 7mG (5') ppp (5 ') G, 1 jug 
plasmid DNA, and 40 U of SP6 RNA polymerase. One juCi of 
H3-UTP (specific activity; 19 Ci/mmol) (Moravek 
Biochemicals, La Brea, CA) was included in the reaction as 
a tracer to permit quantitation of mRNA. Incubations were 
carried out at 37°C for 4 hr in a closed incubator. After 
4 hr, the reactions were treated with 2 U of DNase I for 15 
min at 37°C, extracted once with phenol/chloroform/isoamyl 
alcohol (25:24:1) and then were ethanol precipitated 
(Sambrook et al., 1990). Unincorporated nucleotides were 
removed by passing the reaction mixtures through a NICK 
column (Pharmacia, Alameda, CA). The mRNA transcripts (585 
bases long) were eluted from the NICK column with 0.4 ml of 
10 mM Tris buffer, ImM EDTA, pH 7.5, recovered by ethanol 
precipitation and then washed with ice-cold 75% ethanol.
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Oligonucleotide and CC-1065 Binding to mRNA
EIAV mRNA (9.9 nmol-P; 3.6 n g; 17 pmol mRNA) was 
incubated with 1.2 (equivalent to 72-fold excess over 
target site in mRNA), 0.6 (36-fold), or 0.17 (10-fold) nmol 
antisense oligonucleotide alone or in the presence of 4.8, 
2.4, and 0.67 nmol of CC-1065, respectively. The same 
amount of mRNA was also incubated with 1.2 or 0.6 nmol of 
noncomplementary sense oligonucleotide alone or in the 
presence of 4.8 or 2.4 nmol CC-1065. mRNA was incubated 
with 2.4 nmol of CC-1065 to determine if CC-1065 itself can 
affect translation. mRNA incubated without antisense 
oligonucleotides and CC-1065 served as positive control.
All incubations were carried out for 45 min at 37°C. After 
incubation, mRNA with antisense oligonucleotides and with 
or without CC-1065 were separated from unbound drug by 
passing the mixtures through a NICK column. The mRNA 
samples were recovered by ethanol precipitation.
In vitro Translation Inhibition Study
The in vitro translation assays were performed using 
wheat germ extracts obtained from Promega (Madison, WI).
The translation conditions were according to the 
manufacturer's recommended protocol. The amount of CC- 
1065-mRNA-antisense complex used in the reactions was 
quantitated by incorporated 3H-UTP and was controlled to 
give 600 ng of precipitated mRNA sample. The incubation 
mixtures were composed of 1 mM amino acid mixture (minus
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methionine), 50 mM potassium acetate, 40 U ribonuclease 
inhibitor, 10 /LtCi of 35S-labelled methionine, 600 ng mRNA, 
and 10 jLtl of wheat germ extract in a final 20 Ml reaction 
volume- Translation reactions were carried out for 60 min 
at 25°C. All the assays were done in triplicate and 
statistically analyzed by Student's t-test.
After incubation, 2 Ml aliquots of reaction samples 
were precipitated on Whatman cellulose filter paper by 10% 
trichloroacetic acid (Sambrook et al., 1990) and the level 
of 35S-methionine incorporation was determined by 
scintillation spectrometry. 3H did not interfere with this 
assay because windows on the scintillation spectrometer 
were set to minimize 3H counts and the maximum 3H in the 
reaction was 700 CPM.
Gel Electrophoresis and Autoradiography
A 5 Ml aliquot of each sample was analyzed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis with a 
20% (0.5% cross-linked) separating gel, pH 9.3 containing a 
10% (4.8% cross-linked) stacking gel, pH, 6.8. Gels were 
cast in 18 X 16 cm by 0.5 mm vertical slab cells (SE 600, 
Hoefer Scientific Instruments). The protein bands were 
separated overnight by electrophoresis at a constant 
current of 12 mA. The gel was run until the tracking dye 
was approximately 0.5 cm from the bottom. The gels were 
fixed twice for 30 min in 25% acetic acid and 7.5% methanol 
and were dried for 2 hr in a closed vacuum system (Hoefer
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Scientific Instruments, San Francisco, CA) at 92°C. The 
dried gel was exposed to Kodak X-OMAT film (New Heaven, CT) 
at —70°C for 72 hr.
Results and Discussion
We have proposed in Chapters 2 and 3 that helix- 
stabilizing, minor-groove binding agents might be 
excellent ligands to use to enhance the stability of 
antisense oligonucleotides and their mRNA targets. Our 
binding and melting temperature studies strongly suggested 
that CC—1065 might be particularly useful for this purpose, 
since only CC-1065 was able to bind and hyperstabilize RNA- 
DNA duplexes, while U-71,184 and distamycin A failed to do 
so.
The target (sense) sequence used in this study was 
chosen for two reasons. The target sequence contains a 
potential drug binding sub-sequence, 51-TATTA, at the 
center of the target core. The target is located about 50 
and 75 bases downstream from the initiation site for env 
and S2. genes, respectively.
The effect of CC-1065 on antisense oligonucleotide- 
based in vitro translation inhibition is presented in 
Table 11. CC-1065 did not enhance the effect of antisense
oligonucleotides when mRNA was incubated with a 10-fold 
excess of antisense oligonucleotides. Translation was 
inhibited by about 50% in the presence of CC-1065 and by 
about 46% when CC-1065 was absent. There was also no

















Table 11. Translation Inhibition by Antisense Oligonucleotides and 
CC-1065.
Tube # Antisense/mRNA’ cc-1065/Antisenseb Trans lationc,d
1 0 0 100
2 10 0 53.5 ± 1.8
3 10 4 50.1 ± 5.1
4 36 0 32.7 ± 1.6
5 36 4 23.1 ± 2.7
6 72 0 32.5 ± 2.0
7 72 4 11.0 ± 0.7
a Indicates relative amount of 20-mer antisense oligonucleotide 
incubated per target mRNA. 
b Amount of CC-1065 molecules incubated per antisense oligonucleotide. 
c The level of translation of each treatment was expressed
as % of the level of control mRNA (without added oligonucleotides 
and CC-1065), which was taken as 100%. The values are expressed 
as mean ± SD.
d The following were different (P<0.05) by Student's t-test: 
tubes 1 and 2-7; tubes 2 and 4-7; tubes 3 and 4-7; tubes 4 
and 5,7; tubes 5 and 6,7; tube 6 and 7.
9 2
difference in level of translation inhibition when the mRNA 
was incubated with an excess of 36-fold (67%) and 72-fold 
(67%) of antisense oligonucleotides without CC-1065. When 
mRNA was incubated with an excess of 3 6- or 72-fold excess 
of antisense oligonucleotides in the presence of CC-1065, 
protein synthesis was inhibited approximately by 77% and 
89%, respectively. The dose-dependence suggests that 
duplex formation and CC-1065 binding are concentration- 
dependent under the current conditions of assay. If 
initial rates were to be evaluated, the dose-dependence 
would be expected to be even more pronounced. This will be 
examined in future studies.
Autoradiography bands of the gel-fractionated protein 
products (envelope and S2) showed less density when mRNA 
was incubated with antisense oligonucleotides and CC-1065 
before translation than when mRNA was translated directly 
without preincubation (Fig. 2).
There was no difference in translation inhibition, 
whether mRNA was thermally denatured before incubation with 
antisense oligonucleotide and CC-1065. This indicates that 
antisense oligonucleotides were able to form duplexes 
directly with target mRNA and CC-1065 could bind those 
duplexes. CC-1065 itself did not inhibit translation.
This agrees with previous findings that CC-1065 was not 
able to bind to single-stranded RNA (Krueger et al., 1985).
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Fig. 3. SDS-PAGE Gel of Transcript Incubated with 
Antisense Oligonucleotide and CC-1065.
(Al, A2) RNA only; (Bl, B2) RNA with 72X 
Antisense; (Cl, C2) RNA with 72X Antisense 
and CC-1065; (D) RNA with 10X Antisense; 
(El, E2) RNA with 10X Antisense and CC- 
1065
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
9 4
Enhancement of antisense-mediated translation 
inhibition by CC-1065 appears to have resulted from 
formation of a hyperstabilized duplex between the antisense 
oligonucleotide and the mRNA target. Binding of an 
antisense oligonucleotides and CC-1065 to mRNA may results 
in the formation of a local nondisplaceable patch over the 
target mRNA site that can block the progression of the 
ribosome complex along the template, and therefore cause 
premature termination of the polypeptide chain elongation. 
It is also possible that the mRNA can be degraded by RNase 
H present in wheat germ extract.
When the experiments were repeated with sense rather 
than antisense sequence, disruption of translation occurred 
to only a small extent (Table 12). This indicates that the 
antisense/CC-1065 inhibition observed was due to duplex 
formation and drug binding rather than just the presence of 
drug and additional oligonucleotides in the translation 
reaction. As expected, autoradiography showed that 
reactions containing sense or sense-CC-1065 yielded a 
markedly less decrease in density of protein bands than the 
reactions containing antisense or antisense-CC-1065 (Fig.
3) .
CC-1065 was never developed to be used as an 
anticancer agent because of a fatal delayed hepatotoxicity 
in mice at sub-therapeutic doses (Martin et al., 1984). 
However, taking advantage of the sequence-selective binding

















Table 12. Translation Inhibition by Sense Oligonucleotides and CC-1065.
Tube # Type of Oligomer" 01igomer/mRNAb Drug/Oligomer % Translation'*1
1 Sense 36 0 80.2 ± 2.3
2 Sense 36 4 85.5 ± 5.8
3 Sense 72 0 105.5 + 3.5
4 Sense 72 4 85.5 ± 2.0
5 Antisense 72 0 32.5 ± 2.0
6 Antisense 72 4 11.0 ± 0.7
a Indicates relative amount of 20-mer sense or antisense oligonucleotide 
incubated per target mRNA 
b Amount of CC-1065 molecules incubated per oligomer.
c The level of translation of each treatment was expressed as % of the 
level of control mRNA (without added oligonucleotides and CC-1065), 
which was taken as 100%. The values are expressed as mean ± SD 
d The following were different (P<0.05) by Student's t-test:
tubes 1 and 3, 5, 6; tubes 2 and 3, 5, 6; tubes 3 and 4-6; tubes 4 and 






Fig. 4. SDS-PAGE Gel of Transcript Incubated with 
Sense Oligonucleotide and CC-1065.
(A) RNA only; (B) RNA with 36X Sense;
(C) RNA with 36X Sense and CC-1065;
.(D) RNA with 72X Sense; (E) RNA with 72X 
Sense and CC-1065; (F) RNA with 72x 
Antisense; (G) RNA with 72X Antisense with 
CC-1065
A B C D E
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characteristic of CC-1065 (Reynolds, et al., 1985), we have 
determined that it can be judiciously targeted to a 
specific mRNA and be used to disrupt the biological 
function of the mRNA, providing the RNA target has a known 
CC-1C65 binding sequence.
The results of present and preceding studies (Chapters 
2 and 3) suggest that tethering of CC-1065 to antisense 
oligonucleotides would be a rational extension of this work 
and should be done in the future. The rationale for such 
tethering is twofold. First, if the CC-1065 ligand is 
tethered to the oligonucleotide, its strong genotoxic 
effects can be confined to the duplexes formed by antisense 
oligonucleotides and the target mRNA. This should minimize 
nonspecific CC-1065-related cytotoxicity. Secondly, the 
helix stability of antisense oligonucleotides can be 
markedly enhanced by CC-1065 and full expression of the 
potential of antisense oligonucleotides can occur. Future 
work will evaluate these concepts.
There are three advantages that can be achieved by our 
strategy. First, low concentrations of oligonucleotides 
might be used to obtain the same biological effects 
currently achieved by traditional antisense approaches.
This can minimize the possible nonspecific effects of 
antisense oligonucleotide approach, especially when high 
doses are administered. Also, reduction in concentration 
of antisense oligonucleotides will give a direct cost
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savings, providing additional costs of tethering the ligand 
do not exceed the savings obtained from reduced levels of 
antisense used. Second, increased stability means that the 
antisense oligonucleotides will be associated with their 
targets longer than with conventional oligonucleotides. 
Third, the length of antisense oligonucleotides can be 
reduced and this would not only result in cost savings but 
also help to minimize non-specific reactions, including 
translation inhibition due to partial hybridizations (Woolf 
et al., 1990).
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SUMMARY
The antitumor antibiotic, CC-1065, and its analog, 
U-71,184, are known to bind selectively to AT-rich sites in 
the minor groove of B-form nucleic acids. The binding is 
highly sequence-selective and results in hyperstabilization 
of the nucleic acids. CC-1065 and U-71,184 can be used as 
possible model ligands to enhance the stability of 
antisense oligonucleotides and mRNA.
To clarify our novel concept, binding and melting 
temperature studies of CC-1065 and U-71,184 were performed 
against 20-mer DNA-DNA and RNA-DNA duplexes to determine 
whether drug molecules can bind to those duplexes and 
hyperstabilize them. A 20-mer sense sequence 
(5'-TTACTTCAGTTATGAGACCA-3') was chosen from the env gene 
of the equine infectious anemia virus. Complementary 
20-mer (antisense) oligodeoxyribonucleotides,
5 1-TGGTCTCATTACTGAAGTAA-3', were made of phosphodiester 
(PO), 100% phosphorothioate (PS), or 100% methylphosphonate 
(MP) backbones.
The binding studies were carried out by incubating 
nucleic acids with drugs for 4 hr at 37°C. The amount of 
drug bound to the nucleic acids was measured by a ratio of 
A260 (amount of nucleic acids present) to A3S5 (amount of drug 
present). The melting temperatures were measured on a 
Gilford 2400 UV/VIS spectrophotometer set at 260 nm. The 
temperature was increased by 0.5°C/min from 20 to 95°C.
99
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Binding to the DNA duplexed with either PO or PS was 
saturated at 2 CC-1065 molecules per duplex; but, DNA 
duplexed with MP could bind only one CC-1065 molecule per 
duplex. One U-71,184 molecule bound to 20-mer DNA-DNA 
duplex regardless of internucleotide structure.
One CC-1065 molecule was able to bind to every 20 
base-pairs in poly(rA)-oligo(dT)20. Similarly, one drug 
molecule of CC-1065 bound to the sense RNA sequence 
duplexed with either PO- or PS-based antisense strand. 
U-71,184 was also able to bind to poly(rA)-oligo(dT) 20 with 
maximum binding at 1 drug molecule per 20 base-pairs.
Tm studies revealed that both CC-1065 and U-71,184 
were able to hyperstabilize DNA-DNA duplex even if one 
strand contained a modified internucleotide bond structure. 
The hyperstabilizing effect of U-71,184 was about half that 
of CC-1065 against DNA duplexed with antisense based on 
either PO or PS; however, CC-1065 and U-71,184 were equally 
effective in stabilizing the DNA duplexed with MP. Only 
CC-1065 was successful in strongly stabilizing the RNA-DNA 
duplex, as evidenced by an increase in Tm by 30°C. With 
distamycin A, only 20-mer AT oligomers showed a significant 
increase in melting temperature (20°C).
The binding and melting temperature studies clearly 
indicate that CC-1065 is a good model ligand to be tethered 
to antisense oligonucleotides as a stabilizing agent.
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U-71,184 and distamycin A are unlikely candidates for this 
purpose .
To further demonstrate whether or not CC-1065 could 
potentiate the translation inhibition potential of 
antisense oligonucleotides, an in vitro translation 
inhibition study was performed using a wheat germ extract. 
mRNA containing open reading frames for env and S2 genes of 
equine infectious anemia virus was used as a template. The 
rational basis was that 20-mer antisense oligonucleotides 
can form duplexes with the mRNA and provide a binding site 
for CC-1065. The subsequent duplex-drug combination would 
not be readily dissociated. Thus the CC-1065-antisense 
combination would constitute a non-displaceable patch over 
the mRNA.
The results of autoradiography of translation products 
agreed with the protein precipitation data. mRNA incubated 
with antisense oligonucleotides and CC-1065 before 
translation produced proportionately low values in both 
autoradiographic density and level of 35S-labelled 
methionine incorporation. Our results clearly justify the 
use of CC-1065 and related structures as ligands to promote 
hyperstabilization of sense-antisense duplexes. This 
antisense technology can be applied as preventative as well 
as therapeutic tools against various diseases in the 
future.
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